Other,betterUnderstanding
Investigation,Investigation
Resistance,shouldOvercomeBeforeClinicalApplication
Symptom,hyperglycemia
Other,uniqueProperties
Other,42Patients
Other,antibody-anchoredMagneticBeads
Other,TBR
Other,bayesianNetworkMeta-analysis
Other,detectionOfCancer
Other,essentialRole
Other,differenceBetweenDifferentBreastCancerSubtypes
Other,relationshipBetweenNlr
Subtype,subtype
Other,importance
Other,axillaryLymphNode
Other,revealed
Other,importantTumor-promotingCells
Other,binaryLogisticRegressionModels
Other,collectedSignatures
Paraneoplastic,likelyParaneoplastic
Other,factors
Other,risk/benefitOfDifferentTreatmentModalities
Other,intracellularLevel
Other,total
Other,currentCancerResearch
Other,variousImportantFunctions
Other,only20Percecnt
Other,mass
Other,Disease
Other,positivelyAssociated
Other,consequentlyHaveDeveloped
Other,NSAIDs
Other,differentialDiagnosisInPatientsWithHistoryOfBreastSurgery
Other,newDesignDouble-layerCapacitors
Other,associatedWithPfsAlthoughAtExtent
Other,microscopicTestingOfHematoxylin
Other,threeDifferentClusters
Other,broadDifferentialDiagnosis
Mechanism,stableBodyWeight
Other,breastCancerYoungerThan45Years
Other,thriceHigher
Other,thatInNon-pcrGroup
Other,differentPhenotypes
Other,boneDensity
Other,population-basedStudies
Other,haveDeveloped
Other,analysis
Other,assessedPreoperatively
Susceptibility,nippleAreolaComplexInvolvement
Guidelines,internationalGuidelines
Other,driven
Other,theirTissues
Hazard,coxProportionalHazardModel
Other,frequentMutations
Disease,cancer
Other,fastingBlood
Survival,10-yearBreastCancerSurvival
Radiotherapy,evenSeveralChemotherapySessions
Other,female
Other,inBreastTumorsKnownAsBreastCscs
Other,4.71
Other,smallPopulation
Other,pre-diagnosticObesity
Hazard,multiresolutionResult
Costs,costs
Other,1984
Hazard,outcome
Other,groups
Other,expressionLevel
Other,similarTowaveletFilter
Cell,inPresentStudyConductedBetweenMcf-7Tamoxifen-resistantLcc2CellLines
Other,opticalCoherenceTomographyImages
Other,comparedToThoseWithPregestationalBreastCancer
Other,tumorigenesisOfCells
Other,imperative
Other,9EuropeanCountries
Other,depletion
Other,oneRandomlyAssignedToAxillaryDissection
Other,mammographicBreastCancerScreening
Other,Using
Disease,elevatedLesion
Other,obtained
Care,theirCare
Other,therapeuticSequencing
Other,level
Other,extensiveExploration
Other,affected
Other,uncommon
Hypomethylation,hypomethylation
Other,12EventsAmong121Patients
Hazard,increasedRiskOfTherapy-relatedMorbidity
Other,descriptive
Susceptibility,stillSeriousHealthProblemIn21stCenturySubjectToManyResearch
Other,opticalAbsorptions
Other,13-hDailyOvernightFast
Other,464Percecnt
Other,pool
Other,medicalDiagnosisOfBreastCancer
Other,diverseBiologicalProcesses
Other,comparisonToCa15-3
Other,geneExpressionUpregulationInBreastCancer
Other,93Percecnt
Other,evenMorePersonalizedFollow-upSchedules
Other,inclusion
Susceptibility,mood
Other,cssBenefit
Gene,vascularAdhesionProtein-1
Other,them
Cell,canDiagnosed
Other,backgroundTrastuzumab
Cell,canIncludedInDifferentialDiagnosisOfMasses
Other,MRI
Other,Information
Other,aimed
Other,paper
Other,moreEffectiveTreatmentOfLungCancers
Radiotherapy,anthracyclineChemotherapyAgents
Other,about30Percecnt
Other,SRC
Survival,synchrotronRadiation
Other,indicative
Correlation,matthewsCorrelationCoefficientOf8038Percecnt
Exposure,potentialImpactOnFertilityAfterTreatment
Other,proteinS-100
Other,seValues
Other,13Percecnt
Other,Pearson
Other,generalRadiologistAboutSystemicDiseases
Other,patient'sMedicalHistory
Other,rnaOligonucleotides
Other,treatmentOfBreastCancer
Care,usualCare
Other,minimalRisksToNormalCells
Other,neonatal
Other,comparedBetween2GroupstheApatinib
Other,recentStudies
Other,withDevelopmentOfHigh-throughputSequencingHaveDiscoveredInTumorousTissues
Other,emergingTechnology
Other,breastCancerRelapse
Other,veryHeterogeneousDisease
Other,treatmentProcesses
Other,resistant
Other,made
Other,show
Other,glut1Expression
Other,massProduction
Other,genesInvolved
Other,decreasedGrowth
Other,lessLikely
Other,initialTreatmentAfterWhich
Other,aim
Other,esr1Mutations
Other,relevant
Other,automatedAnalysisOfClinicallyRelevantHistopathologicFeature
Other,bone-modulatingAgents
Contraception,contraceptionUse
Other,roles
Other,haveUsed
Other,theory
Other,standardizedDataCollection
Other,inFluorescenceImaging
Other,mammographicImages
Other,histopathologicalExamination
Signalling,eralphaSignalling
Gene,RANKL
Other,SP
Other,currentResults
Other,time
Other,newOpportunitiesForDevelopmentOfNovelTherapeuticStrategies
Other,retrospective
Other,younger
Other,given
Other,100000Person-years
Other,scalable
Other,recognizingMethylationStatus
Other,surgicalOutcomes
Phosphorylation,phosphorylationOfAkt
Cell,canClassified
Disease,malignancies
Heterogeneity,intratumoralHeterogeneityOfKindOfTumor
Hazard,adjustedHazardRatio
Other,priorMedicalHistory
Other,incidenceFactorsOfSubsequentLung/bronchusPrimaries
Other,5Îœl
Hereditary,inheritableBi-objectiveCombinatorialGeneticAlgorithm
Other,generallyReserved
Other,clinicalSetting
Other,indispensable
Symptom,bestAvailableEvidence
Other,moreDirectional
Other,supportVectorMachine
Other,intensive
Parameters,intravoxelIncoherentMotionParameters
Hazard,individualRiskOfRecurrence
Other,repair
Other,cancerCounseling
Other,Obesity
Other,processes
Other,proposedForBreastTumorGrading
Other,screeningTools
Cell,panelOfMonoclonalAntibodiesAgainstNewlyEstablishedCellLine
Other,ourStudy
Other,respondents
Other,usefulness
Resistance,physicalActivity
Disease,autoimmuneDiseases
Regulatory,molecularRegulatoryNetworks
Exposure,highestPerformance
Other,significantlyHigherPcrRatesThanPatientsWithLuminalTypes
Other,mixedMethodsDesign
Other,rrm2Expression
Other,after6Months'TherapySignificantlyHigherIn3rdTertiaryGroup
Mechanism,bodyMassIndex
Other,needed
Mechanism,statisticalAssociation
Other,ca15-3Detection
Other,accessToEarlyDiagnosis
Other,accurateMethod
Other,tolerabilitytheApatinib
Other,receiverOperatingCharacteristic
Other,clinicians
Other,determinationOfUnderlyingBiologyWithinTumors
Biopsy,tissueBiopsy
Care,transcriptionFactorForkheadBoxC1
Other,non-ideal
Other,including
Exposure,backgroundParenchymalEnhancement
Other,exon32OfMammalianTargetOfRapamycin
Other,mtorInhibitorEverolimus
Other,atEndOfFollow-upClassifiedRegardingTheirAdherenceToRecommendationsForCancerPrevention
Other,hundreds
Survival,breastSurvival
Other,diagnosisOfBreastCancer
Other,proteinExpressionOfNf-krab-p65
Other,measures
Other,thoughtfulMultidisciplinaryPlanning
Assays,dual-luciferaseReporterAssays
Other,nationwideRegistries
Other,overallMediumSecondTumor-freeTime
Other,multimodalTherapy
Cell,cellInvasion
Other,threeDifferentUsMachines
Other,cTn
Other,features
Other,3GroupsBasedOnTertiarySolubleSt-2Level
Other,significantIncrease
Other,120Patients
Other,recentEpigenomeStudies
Gene,PR
Resistance,theirApplication
Other,parameterUncertainty
Other,networks
Care,cancerCareCenter
Other,acid
Hazard,Risk
Other,europeanCountries
Other,WES
Other,couldPotentialBiomarker
Other,axillaryDissection
Other,necessity
Other,currentMeans
Other,hasPutOnIntrinsicSubtypingBasedInPresenceOfClassicalImmunohistochemistry
Other,PM
Other,higherRisks
Other,subsequentlyAssessed
Other,familyHistoryOfDisease
Other,byWhichObservedInNondestructiveWayThroughThermalAnalysis
Other,PFS
Gene,TP53
Other,TRPV1
Other,breastCancerMcf-7
Toxicity,variousLimitationsIncludingToxicity
Other,2921Posts
Other,preclinicalPhase
Technique,noninvasiveImagingTechniqueForBreastCancerDiagnosis
Other,time-varyingPost-diagnosisLow-doseAspirinUse
Other,35-64Years
Other,designed
Other,desirable
Other,forWomenWithBreastCancerMayMoreFeasible
Other,restoration
Other,Japan
Other,pregnancyOutcomes
Other,Survival
Other,date
Chemical,DDT
Other,traditionalPredictors
Strategy,treatmentStrategy
Other,typeOfCollisionTumor
Other,youngMen
Other,forRace/colorVariableEstimatedWithAdjustmentForStatus
Hereditary,identificationOfDistinctiveGeneticModificationsInDifferentBreastCancerMolecularSubtypes
Other,knockdown
Other,purpose
Other,mainMeasures
Other,77Patients
Other,vap-1ImmunohistochemicalStaining
Other,606Percecnt
Other,lesion
Other,advancesInBreastCancerDiagnosis
Other,propagation-basedPhase-contrast
Other,whenonlyAnalyzed
Other,saudiArabianWomen
Other,stageIi
Subtype,willDifferentRegardingSubtypeAtDiagnosis
Susceptibility,involvement
Other,decreasesInMortalityRates
Signature,intervalBetweenDiagnosis
Other,complexConsulting
Other,Results
Species,woman
Other,brca-associatedCancers
Other,embeddingIntoReproducingKernelHilbertSpace
Other,pi3k/aktSignaling
Other,AMD3100
Other,oestrogenReceptorAlpha
Other,stage
Other,appliedTo70PatientsWithUnilateralRl
Other,T2
Other,article
Disease,amenorrhea
Other,thereforeCentralTarget
Other,20
Other,improvedQualityOfLife
Other,lymphedemaseventyPatients
Other,electricalDouble-layerCapacitors
Other,medianFollow-upOf48Years
Cytology,breastCancerGeneticsInKenya
Other,suspected
Other,highestSe
Other,linearRegression
Other,axillaryLymphNodeOfBreastCancerPatients
Other,femaleSibling
Strategy,policyActions
Other,otherSignificantConcerns
Other,higherProportionOfPatientsWithLymphedema
Other,highestSeInTotalGroup
Other,osteopontin-basedProbe
Other,picture
Other,smallMoleculeInhibitors
Other,learning
Other,knowledgeSummaries
Other,anti-oncogenicRegulationOfMir-34s
Hazard,anticipatedOutcome
Disease,metastasis
Other,ourFindings
Other,taiwanLongitudinalHealthInsuranceDatabase2005
Other,currentFollow-up
Image,image
Other,C1
Scans,chestCtScans
Other,hasRecentlyProposedAsCrucialRegulatorOfTriple-negativeBreastCancer
Susceptibility,cancerSusceptibilityGenes
Other,undifferentiatedNeoplasticCells
Other,deregulatedMirnas
Other,inception-v3Cnn
Disease,Metastasis
Hazard,non-standardLessPromptTreatmentsIrrespectiveOfComorbiditiesWithIncreasedRiskOfMortality/relapse
Symptom,existingEvidenceOnPersonalGoal-settingAmongWomenWithBreastCancerDiagnosis
Radiotherapy,locoregionalRadiotherapy
Other,lungCancerInHuman
Other,Screening
Image,energyImage
Other,BMI
Other,sensitive
Other,ruralSetting
Other,humanEpidermalGrowthFactorReceptor2ReceptorStatus
Care,healthcareUtilization
Other,q12X
Care,multidisciplinaryCare
Other,treatingMedicalTeam
Other,advancedAnalysis
Other,tackled
Care,interventionArm
Other,severalObjectives
Other,means
Other,foundBetweenMolecularSubtypesWithHer2
Resistance,physicalActivityInPatientsWithMetastaticBreastCancer
Other,effectiveness
Radiotherapy,palliativeChemotherapy
Other,multidisciplinaryAssessment
Other,goal-setting
Other,mostStigmatization
Other,72Months
Other,This
Other,Radiotherapy
Other,components
Other,0-5Years
Other,mostCommonCancerOfAdolescentsAgedAccountingFor56PercecntOfInvasiveBreastCancerInWomen
Other,historyOfBreast-conservingSurgery
Other,itsRole
Other,standardMethod
Cell,canImportantToDiagnosis
Other,trastuzumabInitiation
Other,We
Other,lowDiagnosticSensitivityForWomenWithDenseBreasts
Other,severalIntelligentTechniques
Other,concentrations
Other,inConclusionPathogenicFeatureInPrimarySamples
Hazard,shouldPerformedInAtRisk
Other,tumorGrowth
Other,scrutinized
Exposure,greatClinicalImpactForTumorDiagnosis
Other,inexpensive
Other,site-specificBindingLeadingToImprovedCancerTreatmentWithMinimalRisksToNormalCells
Other,specificGroups
Other,ronInternalization
Other,themselves
Other,subtype-specificPrognosticSignatures
Strategy,multimodalityTreatmentStrategy
Other,summary
Other,twenty-twoPatients
Susceptibility,barcodeMode
Other,tendency
Other,drastic
Other,broadUseToPatients
Other,microfluidicsBiomarkerDetection
Other,mammaryMetastasisFromCarcinomaOfOvarianOrigin
Disease,triple-negativeBreastCancers
Other,qualityOfLifeOfPatients'Spouses
Other,inhibited
Other,actualIncidence
Other,40Percecnt
Other,virtualRecombinedImagesFromLeImages
Other,Porto
Other,mostCommonNeoplasms
Other,commonPlatformForStakeholdersIncludingPolicymakers
Other,expressionOf6CirculatingMirnasInOperablePatients
Cell,canUsed
Other,developmentOfBreastCancer
Other,differentmethodsOfSelf-treatment
Other,activatedComplex
Other,aberrantlyExpressed
Other,SD-CNN
Other,targetedTherapies
Other,AUC
Other,shallowCnn
Other,solidTumors
Other,imagingModalities
Other,duringAgeAssociatedWithIncreaseOf8MoreFemaleBreastCancerCasesPer100000DuringAge50-54
Other,patientsWithHer-2PositiveExpression
Parameters,quantitativeParameters
Other,discrete-timePartiallyObservableMarkovDecisionProcess
Resistance,endocrineResistance
Other,firstSteps
Symptom,heavySymptomBurden
Other,factor
Other,Ki67
Other,levels
Other,fabricated
Advantage,interest
Other,morcFamilyCw-typeZincFinger4Overexpression
Radiotherapy,needForNodalRadiotherapyInSpecificSituations
Other,tangshanPeople
Other,G
Other,additionalAnalyses
Other,oneMutation
Other,practitionersKnowledgeable
Other,foxc1-knockdownBt549Cells
Other,therapeuticTarget
Other,expressionLevels
Other,timeInMostCountries
Other,immunohistochemicalTests
Other,dissection
Other,mastectomiedPatients
Other,theirParticularity
Advantage,goodDiagnosticPerformance
Other,70-year-oldWoman
Susceptibility,collectedFromElectronicHealthRecord
Mechanism,associationStudy
Other,humanBiofluid
Susceptibility,greaterthanorequalto10PercecntDecline
Other,optimalCut-offValue
Other,22Deaths
Other,obtainedFromPatientsWithBreastCancer
Other,medianTime
Other,comparisonOfPredictedIncidenceOfBreastCancerWithActualIncidenceInPopulation-basedStudies
Other,twoCases
Technique,advantageOfHigh-throughputLuminexTechnique
Other,dominantArms
City,howeverGreaterforPatientsTreatedInAlmatyCity
Susceptibility,noticeableDrugLoadingCapacity
Other,Use
Other,variousMethods
Other,figures
Other,8155Patients
Other,aromataseInhibitor-inducedBoneLoss
Disease,dyspareunia
Other,differentDetectionRatesInBreastCancerPatients
Other,ET
Other,methylationStatusOfPcdh10InBreastCancerTissues
Other,133Controls
Other,Zt/g4-MMAE
Other,hasWidelyUsed
Other,problem
Other,initialPresentationOfInvasiveBreastCancer
Susceptibility,capacity
Other,hasMade
Other,advancedDiagnosticImaging
Other,third
Other,that
Other,effective
Other,down-regulatedInTissues
Care,attention
Other,LVI
Other,intopreGroups
Other,newSpecificMarkers
Other,esr1Alterations
Other,womenWithMore70PercecntOfPatientsTreatedWithHormonalTherapy
Other,mayUsedForTumourShrinkagePriorToSurgery
Other,Therapies
Other,multivariate
Other,disposition
Other,faSignalingNetwork
Other,balb/cNudeMiceBearing
Other,adjuvantEndocrineHormonalTherapy
Other,accumulatingResults
Other,old
Risk,mostProminentCause
Other,56Patients
Other,predictors
Other,featuresFromImages
Other,group
Protocols,differentProtocols
Other,mortalityRate
Disease,malignancy
Other,strong
Other,paTreatment
Other,standardMethodForEvaluationOfProposedPrognosticTumourMarkers
Other,positiveTreatment
Other,signalAmplificationStrategies
Other,grade
Other,furtherDevelopment
Other,suchLowIncidence
Other,commonMalignancyWorldwide
Other,microscopicImages
Other,Steps
Survival,threeOverallSurvival
Other,tumor-bearingMiceOfMcf-7BreastCancerCells
Other,convolutionalNeuralNetworks
Other,700
Other,detectionOfMicrocalcificationInMammograms
Other,age
Disease,pleuralMetastasis
Other,occurringCancers
Other,ourBreastCancerPatients
Cytology,surfaceMorphology
Other,bloodSamples
Susceptibility,generalHealth
Other,furthermoreAssociated
Other,731Percecnt
Other,malignant
Disease,tumours
Resistance,netvizzApplication
Other,antibodyDrugConjugates
Other,effectsOfTreatment
Other,necessary
Other,0.0001
Other,quality
Other,couldDetectedByMammographyBySelf-detection
Other,invasiveCarcinomaBreast
Other,geneExpressionLevel
Other,nanoplatform
Disease,AD
Other,scffbxo22-mediatedKdm4bDegradation
Other,patientsWithMAmongThem
Subtype,definedSubtype
Other,involved
Other,women'sCancerAccounting
Other,knowledgeOfM
Other,highlyPenetrantGenes
Signature,signature
Other,negativelyCorrelatedWithLvef
Parameters,parameters
Subtype,oneSpecificSubtype
Other,importantRole
Other,childbearingReasonsIncluding
Other,methodsDesign
Other,interplay
Other,observationalStudies
Autoantibodies,autoantibodies
Other,conditions
Other,pleuralDiseaseProgression
Other,17MillionPeopleWorldwide
Exposure,model
Other,drawbacks
Other,contribution
Radiotherapy,theirRelatedMarkersAtDifferentPointsOfChemotherapyRegimensInMetastaticBreastCancer
Other,established
Other,patientsWithLocoregionalInSouthernPortuguese
Other,improvedUnderstanding
Other,eventualKnowledge
Other,pattern
Other,preoperativeUnderstanding
Other,age-matchedSystematicRandom-samplingMethod
Other,inTotalDiagnosedUnderAgeOf50
Other,tightDoctor-patientCollaboration
Other,rate
Other,detectionOfBreastCancerInWomen
Other,38Months
Other,bilateralMastectomies
Other,furthermoreSignificantlyMoreLikely
Other,characteristicsInsideTumors
Cell,canTherapeuticTargetForNextGenerationOfSerms
Other,mir-193b-3pBindingTo3UntranslatedRegionOfMorc4
Other,shouldElaborated
Other,breastCancerTissueMicroarrayWithAccessToReceptorAnalyses
Other,macrophages
Other,oestrogenReceptorCofactors
Other,pH
Other,couldDetectedEarly
Hazard,riskOfDeath
Other,0.46
Other,itsExpression
Other,5CmLess
Other,tomography
Other,she
Other,prevention
Other,1973To2014
Other,typical
Other,molecularAnalyses
Symptom,firstSymptom
Other,complex
Gene,ESR1
Gene,DESI-MSI
Risk,cause
Other,cancerTreatment
Other,dcisDiagnosis
Other,includedInStudy
Other,developmentOfSubsequentLung/bronchusCancer
Other,suutaneousLymphaticChannelsInReal-time
Other,ELISA
Other,12331Users
Other,documentedAsImportantTumor-promotingAgentForSeveralHumanCarcinomasIncludingBreastCancer
Oxidation,oxidationPeakCurrent
Other,childHealth
Other,treatment
Symptom,symptomBurden
Other,imagingIndexes
Other,radiationTherapy
Image,netherlandsCancerRegistryOf37230PatientsWithEarlyBreastCancer
Chemical,omega3FattyAcids
Other,prognosticFactorIndependentOfOtherClinicalVariables
Other,sensitivityOf786PercecntRespectively
Other,lowCountries
Vivo,evaluatedInVivo
Other,neuralNetworkClassifier
Other,levelsOfEralphaProtein
Other,her2-positiveA
Long-term,inLongTermHasFound
Other,significantChallenge
Other,secondaryConfirmationOfSignalAccumulationUsingNearInfraredFluorescentImaging
Guidelines,guidelines
Other,tumorNeoangiogenesisSimilarToBreastMagneticResonanceImaging
Gene,PALB2
Cell,theyCanImpactOnQualityOfLifePresent
Other,responsibleMechanisms
Other,resultsDiagnosed
Other,additionallyRevealed
Phenotype,textureFeatures
Other,conjugatedEquineEstrogen
Other,malignantProgressionOfBreastCancer
Other,better
Care,maintenanceOfErCancerStemCells
Other,876PercecntRespectively
Other,oncogenesEsr1
Correlation,expectedInverseCorrelationOfSerumDdtsWithBmi
Other,significantDifference
Other,understudied
Other,differentiallyExpressedInBreastCancerCells
Other,review
Other,novelInsightsIntoPotentialMechanismsAssociatedWithBreastCancerPathogenesis
Risk,secondLeadingCause
Other,analyzedBeforeAnd
Other,Univariate
Other,lobularCarcinoma
Other,advantages
Other,diagnosticAccuracy
Other,17Years
Other,specimen
Vulnerability,vulnerability
Other,diverse
Other,strongContrastWithImagingModalities
SNVs,SNVs
Other,lipidProfiles
TAAs,TAAs
Other,EMH
Other,simulatedInnerBreastTissue
Other,dysregulation
Cell,capacitance
Other,haveStudiedInTermsOfCrosstalkBetweenEstrogenReceptorAlpha
Other,SUVmax
Other,added
Other,clinico-epidemiologicalFeaturesOfBreastCancer
Other,ourTheoreticalAnalysis
Immunohistochemical,immunohistochemicalAnalysis
Other,DAU
Susceptibility,diminishedOncospheroid-formingCapacityOfBreastCancerCells
Autoantibodies,roleOfAutoantibodiesInEarlyCancerDiagnosis
Other,They
Other,suchStandardization
Activities,activities
Other,replaced
Other,hasFound
Other,tool
Disease,neoplasms
Other,18.791
Other,significantlyHigherBaselineBpeLevelsThanPostmenopausalWomen
Strategy,strategy
Other,poorPrognosis
Gene,SOX9
Other,incidenceFactors
Other,hasAssociated
Other,Kazakhstan
Other,insight
Other,firstFiveFacebookOpenBreastCancerGroupsInYear2016
RNAs,RNAs
Other,histologicGradeInBreastCancer
Other,parpInhibitors
Other,mainlyEurope
Other,patients'Self-monitoring
Cell,canImportant
Other,patientsWithNeoplasticDisease
Other,4Categories
Other,mastectomies
Other,molecularDiagnosisMethodMake
Autoantibodies,multiplexedAssayForDetectionOfAutoantibodiesInCanineTumours
Disease,breastCancer
Other,dynamicContrast
Susceptibility,harmToHealthAmongRuralWomenWithIncrementalCost-effectivenessRatio
Other,induction
Other,caloricRestriction
Other,experiences
Disease,inflammatoryTumour
Other,erEvaluation
Other,value
Other,x-rayMammography
Other,furtherTissue
Other,massiveCircrnas
Other,receiverOperatingCharacteristicCurves
Other,haveReportedInOnly003-06PercecntOfBreastCancers
Other,mrnaExpressionLevelOfPcdh10
Other,Familiarity
Other,modified
Other,481Women
Other,relativeThoseOfPostmenopausalPatients
Other,areUsed
Image,appearance
Other,accuracy
Other,base
Other,876Percecnt
Other,haveDescribed
Other,expressionOfMir-511InBreastCancer
Other,patientsWithHistoryOfBreastSurgery
Other,currentlyInsufficient
Other,mostEffectiveTechniqueused
Other,the
Other,diagnosisOfPatientsWithBreastCancer
Radiotherapy,correctionMethod
Other,target
Survival,survivalThanAdjuvantTherapy
Other,finding
Susceptibility,health
Other,potentialTherapeuticTarget
Other,shorterIntervalsBetweenD
Other,inhibition
Technique,additionalLocalControl
Vulnerability,consensusOnAssociationBetweenExposureToDdt
Other,comprehensiveResearchData
Other,a
Other,robust
Other,952PercecntOfthePostmenopausalWomen
Other,57PercecntOfPatients
Neuromas,only35CasesOfTraumaticBreastNeuromas
Other,non-nsaidUsers
Care,rural-basedTertiaryCancerCareCenter
Other,breastCancerScreening
Other,eralphaTranscription
Other,futureClinicalStudies
Other,mammograms
Other,howeverWidelyUnderstood
Other,clinicalFeasibilityOfCtcIsolation
Other,spdMatrices
Disease,collisionTumor
Other,10Percecnt
Other,vap-1Expression
Other,stagingSystems
Disease,carcinogenesis
Hazard,riskFactorsOfLvi
Other,detectionofBreastCancer
Disease,obesity
Other,explored
Other,multiplexAssay
Other,thusCritical
Other,method
Other,potentialOfAionAsEffectiveMultimodalContrastAgentForBreastCancerDiagnosis
Other,haveCenterstage
Species,human
Other,1
Other,analysed
Other,objective
Exposure,theirQuestionableImpactOnMortalityOnIncidenceOfAdvancedTumors
Image,imageQuality
Other,lower
Resistance,choiceOfChemotherapyInBrca-associatedCancers
Other,252Percecnt
Other,alreadyWell-established
Other,different
Other,lungChanges
Other,decreasedBpe
Other,opportunities
Mechanism,bodyWeight
Other,transport
Other,westernBlot
Other,nsaidUsers
Other,obtainedFeatures
Other,infraredFluorescentDye
Other,multipleBiological
Other,FFDM
Other,progressionDisease
Other,higherRatesOfMisdiagnosisForBreastCancer
Other,Barshi
Other,breastTumorProgression
Other,withBetterDrugDeliveryPotentialOfNon-sphericalShapesHaveRecentlyInvestigated
Other,haveClarified
Other,oneRegionAnother
Other,veryRareCaseOfTraumaticBreastNeuroma
Other,therapy
Other,breastScreening
Other,clinicalDepression
Other,estrogen-receptorAmongOtherMarkers
Other,monteCarloFeatureSelection-basedFeatureSelection-basedComputationalMethod
Other,reverseTranscription-quantitativePolymeraseChainReaction
Other,asymptomaticWomen
Other,Japanese
Other,cnvsOfDifferentCancers
Other,defined
Other,adPatients
Other,patientsWithBreastCancer
Susceptibility,improvement
Other,lowClassificationAccuracies
Signature,response
Other,available
Other,alternativeMeans
Survival,breastCancer-specific10-yearSurvival
Other,theirAbilityOfPrognosisPredictionInTheirOriginallyTargetedPopulationsOfBreastCancer
Other,limitations
Other,shown
Other,Acupuncture
Cell,canHeavilyInfluenced
Mechanism,associationBetweenRace/colorInWomenWithBreastCancer
Other,regression
Other,Cells
Other,whereFacilitatedBySurfaceModificationOfNps
Long-term,long-termEstimates
Other,markers
Other,CTCs
Other,spectrum
Disease,polycysticOvarySyndrome
Other,smallProportion
Other,availableContrastAgents
Other,youngWomenWithInvasiveLobularCarcinoma
Mechanism,body
Other,firstDiagnosis
Other,unmetPsychosocialNeeds
Other,erImmunohistochemistry
Other,directEffects
Other,majorCscMarkersDescribedInInvasiveBreastCancer
Other,investigatedOnly
Species,women
Other,thatOfOtherCountries
Other,esr1-activatingMutations
Other,patientsWithReducedBaselineLvef
Susceptibility,thusInRecentYearsDemand
Other,carbohydrateRestriction
Other,comparedBetweenMetastaticSlns
Other,sample
Other,otherData
Other,alternativeOption
Other,newTreatmentRegimens
Hazard,riskFactorForLung/bronchusCancer
Susceptibility,identificationOfPredictiveBiomarkersForSelectionOfOptimalTreatment
Subtype,triple-negativeSubtypeMda-mb-231Cells
Other,microRNAs
Other,largelyConsistent
Other,bilateralBreastLumps
Other,greatProgress
Other,subsequentRadiomics
Hazard,outcomeInEr-positive/humanEpidermalGrowthFactorReceptorType2-negativeBreastCancersWithHighHazardRatiosIndependentlyOfOtherMarkers
Other,upregulated
Mechanism,termsOfMechanism
Care,healthCareSector
Other,Associations
Other,inclined
Other,DSCAM-AS1
Other,sensor
Other,areaOfResidence
Other,KDM4B
Other,manyBreastCancerPatients
Radiotherapy,systemicChemotherapy
Other,promoterMethylationInCertainTypesOfHumanTumors
Other,furthermoreMoreLikely
Species,patients
Other,unknown
Other,sparseCoding
Other,sometimesMistaken
Hazard,resultOfPreviousOrbitalBiopsy
Other,Increase
Image,whenActiveUse
Exposure,itsDiagnosticPerformance
Other,existence
Other,inverselyCorrelated
Technique,controlGroup
Other,sideEffectsOfBreastCancerTherapiesIncludingHotFlushes
Other,poor
Cell,breastCancerCellInvasion
Other,long-termUse
Other,Nek6
Other,accuracyScores
Other,similarPfs
Presentations,presentations
Other,medianFollow-upOf9Â·
Signature,partialPathologicalResponseWithLargeAreasOfTumourRegression
Gene,ERBB2
Other,conclusionsWomen
Other,properAccessToDiagnosis
Other,occurrenceOfBreastCarcinoma
Other,keysToSuccessfulChestWallResectionForLocallyRecurrentBreastCancerAfterMastectomy
Other,excision/lumpectomy
Other,recommendations
Symptom,symptom
Correlation,highCorrelation
Other,prospectivelyFollowedFor3YearsSinceDiagnosis
Other,breastConservation
Other,ddtSprays
Other,apoptosis
Other,microscopicExamination
Other,feasibleCtcIsolationTechniques
Cell,canConsidered
Other,physician
Susceptibility,variablesPredictiveOfNippleAreolaComplexInvolvementInPatients
Survival,intralaboratoryValidationSet
Care,analyzedtheOperationTime
Other,NMA
Disease,her2-positiveBreastCancer
Other,thanCapecitabineGroup
Other,pathogenesisOfBreastCancer
Other,fewPercentOfWomen
Other,mayUsed
Other,49CedmCasesCollectedFromMayoClinic
Other,agreement
Other,gonadotropin
Other,Mutations
Other,youngerAge
Other,group1
Other,thanDcis
Other,twoYears
Cell,canEffectivelyTreatedByEndocrineTherapy
Other,nano-genosensor
Chemical,anastrozole
Other,contrast
Other,outcomesOfEstrogenReceptorPositive
Other,deepLearning
Other,0.84
Other,thereforeCriticalSignificance
Other,treatmentRegimens
Other,caseRecords
Survival,significantlyCorrelatedWithOverallSurvival
Other,highExpression
Other,haveProducedInLaboratories
Other,inTotalMatchedToCasesOnBirthYear
Other,noninvasive
Other,1YearTo5Years
Susceptibility,specificallyPlacedOnInflammatoryBreastCancerWithSkinInvolvementOnCutaneousMetastasesToBreastFromBreastCancer
Image,reverseActiveLearningForClassificationOfHealthyBreastTissue
Other,significantlyYoungerAge
Other,neutrophil-to-lymphocyteRatio
Mechanism,potentialMechanism
Other,resonanceImaging
Other,Anthracyclines
Other,needsInPrevention
Other,accomplished
Other,54BreastCancerPatients
Other,epidemiologicalFeatures
Resistance,course
Other,singleMetastaticSite
Other,S+RT
Technique,cancerControlPlanning
Resistance,anti-tumorActivity
Other,analyzedRetrospectively
Other,utilized
Survival,flowCytometry
Other,down-regulated
Other,underutilized
Other,localTherapyOfBreastCancer
Other,mustAddressed
Other,shallow-CNN
Advantage,good
Care,neededAcrossCareContinuumEspeciallyInLow-resourceSettings
Oxidation,greaterthanorequalto10PercecntReductionInLvef
Cytology,invasiveLobularHistology
Other,detected
Other,yearRfsrate
Other,mutationEvents
Other,nek6Expression
Vulnerability,estrogenicExposure
Other,147Patients
Other,62Years
Other,AYAs
Other,inConclusionStillNecessaryForAdoptionOfCtnAsRoutineClinicalBiomarkerInPatientsWithBreastCancer
Other,techniques
Other,-25-diphenyltetrazoliumBromideAssay
Other,1444Women
Other,inPrimaryBreastCancerTumorsExpressedDuringNeoplasticTransformation
Other,racialDisparity
Other,properties
Other,highVolumeAcademicCenters
Other,radiomicsScore
Other,TAMs
Other,mostPretermBirth
Other,aspirinUse
Other,loss
Other,CEDM
Other,ctcsFromPeripheralBlood
Disease,advancedBreastCancer
Other,breastCancerClassification
Other,specialType
Other,linerRegressionAnalysis
Mechanism,pdgfs/pdgfrsAxis
Other,newBilateralIntrapulmonaryNodules
Other,primaryPurposeOfPeriodicMammogramsInScreeningProgramsIs
Other,progressionOfTumorInvasionInBreastCarcinoma
Disease,carcinoma
Other,Cases
Other,recurrentWords
Other,rates
Other,wordCloud
Other,goal
Other,positivelyCorrelated
Other,multi-stimuli-responsiveTheranosticNanoplatform
Other,contextOfBreastCancer
Other,malePatients
Other,haveReported
Other,predominant
Other,tumourSpread
Other,pD1542yMissenseMutation
Other,future
Other,estimates
Other,understood
Other,breastMetastases
Other,whenGiven
Other,twentyUniqueEsr1Mutations
Gene,BRCA1/2
Other,screened
Other,willTested
Oxidation,greaterthanorequaltoReduction
Other,downregulated
Other,monteCarloFeatureFeatureMethod
Other,microrna-22ExpressionLevels
Other,phForHer2AgainstHer2-overexpressedBreastCancer
Susceptibility,whenIntegratedWithinCountry/region'sHealthPlan
Other,regressionModels
Other,determine
Other,patientsWithMeasurementErrors
Other,cancerResearch
Hazard,increasedRisk
Other,medicalHistory
Other,Recurrences
Other,formed
Other,breastCancerPatients
Other,otherInotherTertiaryCentres
Other,suutaneousEcchymosis
Disease,heterogeneousDisease
Other,subsequentPrimaries
Other,couldDetected
Other,present
Other,impairedBaselineCardiacFunctionExperience
Other,referenceForClinicians
Other,youngMalePatients
Other,significant
Other,circulatingSolubleRankl
Other,tools
Other,casesWithoutMetastasisOnDiagnosticImaging
Other,feasible
Other,preoperativeCytologicalDiagnosisOfBreastCancerMetastasesInRegionalLymphNodesIn84Patients
Disease,fanconiAnemia
Other,sufferingFromWoman'sDisease
Other,ratio
Other,pleurodesis
Other,howeverHaveClarified
Hazard,hazardRates
Other,familySupport
Other,4Domains
Other,0.00001
Disease,paraneoplasticNeurologicSyndromes
Other,ageGroups
Other,delaysinTreatment
Other,twoCasesOfMimicsOfBoneMetastasis
Survival,overallMedianSurvival
Other,circulatingTumorCells
Other,476Years
Other,conducted
Symptom,novelStrategiesForDiagnosisOfBreastCancerWithHyperglycemia
Other,thusPotentialTherapeuticTarget
Other,benignBreastLesions
Care,clinicalCare
Other,solicitations
Other,microfluidicPlatform
Other,quality-of-lifeFactorsForSurvivorsIncludingSexualDysfunction
Other,muchFocus
Other,prospectiveStudies
Other,67BreastCancerSamplesFrom66Patients
Other,breastCancerSubtypesa
Hereditary,distinctiveGeneticModifications
Mechanism,significantAssociationBetweenLevelsOfNek6
Other,MP
Other,gynaecologicalMetastases
Other,mayIndicativeOfBenignLesion
Other,neutralEffects
Other,mostWomen
Mechanism,associationBetweenPost-diagnosisLow-doseAspirinUse
Other,group2
Other,earlyStage
Other,her2Overexpressing
Other,alarmingLevelGlobally
Chemical,estrogen
Other,highMortalityRateForFemales
Other,overexpressed
Other,womenWithG
Other,recentlyDiagnosedBreastCancer
Disease,AION
Other,formedByCo-encapsulationOfNear-infraredFluorophoreInPegylatedMicelles
Other,oedema
Other,patterns
Other,MSOT
Disease,tumor
Other,initiationOfBreastMalignancy
Other,manufactured
Other,urgentClinicalProblem
Other,effectivenessOfDifferentNpatsOnQolInPatientsWithBreastCancer
Other,common
Other,improvedCancerTreatment
Other,foodRecommendations
Other,avoidance
Other,scope
Other,xenograftMice
Other,inflammatoryDiseases
Other,included
Other,odds
Other,propensityScoreMatchingAnalysis
Other,luminalB-likePatients
Other,breastCancerTherapy
Other,likely
Other,addition
Other,inPaperUsed
Other,breastCancerCells
Other,premenopausalPatients
Other,whenSuspected
Cell,canDifficult
Other,Factors
Other,tumorSuppressorGene
Other,developed
Other,resultsOfStudy
Strategy,system
Other,moreAdvancedStages
Other,992Percecnt
Other,report
Hazard,worseOutcome
Other,proliferation
Other,appropriateDiagnosisOfBreastCancer
Other,25CaseReports
Other,thepresence
Other,Analysis
Other,real-time
Short-term,promisingShort-termStrategiesPriorToTreatmentAdministration
Other,indicatorOfNacEffectiveness
Other,icgFluorescenceMethod
Other,68Percecnt
Other,immunohistochemicalDetectionOfErPerformedInRoutineClinicalPractice
Other,ruralCancerHospital
Other,complexDueToPotentialFoetalRisksInSettingOfMaternalTreatment
Other,incidentalFinding
Other,shouldCo-managedByCardiologist
Other,manyResearchers
Other,30TBreastMagneticResonanceImagingExaminations
Other,90PercecntOfPatientsWithRecurrence
Other,comparedBetweenPremenopausalGroupsBetweenPcrGroups
STs,stsOfDeath/relapse
Mechanism,significantAssociationBetweenRs5743810AllelicFrequency
Other,uniqueEsr1Mutations
Other,longerPfs
Other,408
Other,previousCervicalCancerScreening
Other,bio-metal-organicFrameworkCoated
Other,505Percecnt
Advantage,mayGoodChoiceForUnilateralPtmc
Other,allBreastCancerPatients
Other,dictionaryLearning
Other,anti-ronMonoclonalAntibodyZt/g4-drugMonomethylAuristatinEConjugate
Other,differenceBetweenClearcellPlatformsForIsolatingCtcs
Other,sox9NucleusEntry
Long-term,theirLong-termSurvival
Other,history
Resistance,endocrineTherapyResistance
Image,february2012InNargisDuttMemorialCancerHospital
Other,developmentOfLymphedema
Other,Chi
Township,country
Other,hormone-dependentPositiveBreastCancer
Other,formulationOfEffectiveManagementPlanForAt-riskWomen
Other,manyFeatures
Other,keys
Other,amongThemNewlyIdentifiedInStudy
Other,417Percecnt
Other,breastExamination
Other,mostRelevantKind
STs,STs
Other,99PercecntAccuracyInTermsOfClassification
Other,disease
Other,non-standardPromptTreatments
Cell,cellProliferation
Other,willTestedThroughEuropeanMyPersonalBreastScreening
Correlation,correlation
Other,significanceOfTime-trends
Other,prognosticSignificanceOfNlrInEarlyStage
Exposure,crucialImpactOnDevelopmentOfBreastCancer
Other,recentDanishCohortStudy
Susceptibility,automaticIntraoperativeIdentificationOfBreastCancerMargins
Disease,pretermBirth
Other,occurring
Other,advancedStage
Other,tumor-associatedMacrophages
Other,4
Other,markerBands
Other,information
Other,description
Other,fusionProteinsWithHaloTag
Care,cancerCareSystems
Other,ctnLevels
Other,mostPrevalentType
Other,howeverUnderutilized
Other,alsoAssessedByQrt-pcr
Other,improved
Other,adverseEventsExceptDegreeI-iiBleeding
Other,hypothesis
Other,attempted
Other,leucocytes
Disease,metastaticBreastCancer
Other,risks
Other,megakaryocytes
Other,30DoublingTimesNecessary
Other,evaluation
Parameters,pharmacokineticParameters
Survival,releaseProfile
Other,nonparticipation
Other,overexpression
Other,access
Other,oneScreeningProgramme
Other,vital
Other,personalDecision-making
Strategy,screeningStrategy
Other,penalizedLogisticRegression
Other,virtualReality
Other,benign
Disease,DCIS
Other,msotImaging
Other,inBelgiumMostFrequentWomen'sCancerAccountingForTo353PercecntOfCases
Other,Mammographic
Other,applied
Other,employed
Care,primaryCareProvider
Other,majority
Other,novelMethod
Other,importantInsightsIntoDiagnosisOfPatientsWithDisease
Other,used
Gene,NCAM1
Other,moreInformationAboutFurtherStratificationOfBreastCancerSubtypes
Risk,commonCause
Other,FOXC1
Other,pathologyForFurtherFollow-up
Other,patientsByTrastuzumab-pretreatment
Other,detectionRate
Other,matchedHealthyTissues
Other,contrastAfterInjection
Cell,cancerStemCellHypothesis
Other,effectsOfPcosOnRisksOfGynecologicCancer
Other,correlated
Other,73-yearOldWomanPresentingWithLeftBreastLumpClinicallyIndeterminate
Hazard,risk
Other,percent
Other,segmentationAlgorithm
Other,tissue
Other,additionalInformation
Other,ecchymosis
Other,elderlyPatients
Hazard,coxHazardRegressionAnalysis
Other,detection
Other,diagnoses
Other,decreases
Other,Transcripts
Other,adherence
Other,baselineSolubleSt-2Level
Image,enhancementOfImage
Other,asInCaseShouldAlwaysKeptInMindSpeciallyInHighVolumeCenters
Other,successfulFunctionalizationOfNanocompositeOfSpecificSequenceOfAminatedComplementaryOligonucleotideOfMirna-21
Other,preoperativeDiagnosis
Hazard,highestRisk
Other,er-dependentTranscriptionalActivationViaTransactivationFunction1
Other,morc4Silencing
Other,twoChlorambucilPlatinum
Neuromas,traumaticBreastNeuromas
Other,M
Other,stronglyPositive
Other,clinicalBreastExaminationCoupledAsPrimaryTool
Advantage,widespreadInterest
Other,screeningPrograms
Hazard,decreasedRiskOfBreastCancerInFemaleAdPatients
Susceptibility,changesInHealthBehavioursAfterBreastCancerDiagnosis
Other,bareCapillaries
Other,evidence-basedRecommendations
Other,kernelApproach
Other,stillObscure
Other,mostCommonAgentsUsedInBreastCancerTreatment
Other,earlyBreastCancerSurgery
Other,CGI
Other,invasion
Other,shouldPerformed
Signature,three-lncrnaSignature
Other,area
Strategy,short-termStrategy
Other,prohibitivelyExpensive
Other,haveReportedMainlyAfterMastectomy
Other,currentAnalysis
Other,BRCAs
Other,65Patients
Other,year
Advantage,handicap
Exposure,equivalentPerformance
Other,sentinelNodes
Other,heterogeneous
Other,worldwideHighestAge-standardizedBreastCancerIncidence
Other,circRNAs
Other,MCC
Other,localizedDescriptionOfBreastCancer
Disease,triple-negativeBreastCancer
Other,differentiation
Other,drugBinding
Risk,commonCauseOfMorbidity
Other,negativeEffects
Other,clinicalBreastCancerTrials
Other,5-khzFrequencies
SNVs,sharedSnvs
Other,histologicalExamination
Other,1000Patients
Other,hasReported
Mechanism,associationBetweenTumorUptakeInInvasiveDuctalCarcinoma
Other,0.520
Other,evolve
Other,mostPervasiveTypeOfCancerAmongWomen
Other,criticalRole
Survival,presentedWorkForFeatureExtraction
Symptom,effectOfDdtSpraysOnBreastCancerIncidenceRate
Other,clinicopathologicalCriteria
Susceptibility,healthCenters
Other,z-test
Other,howeverKnown
Other,Anemia
Other,clinicalVariablesAmongDifferentGroups
Other,denosumabInjection
Other,obscure
Other,standard
Disease,metastaticDisease
Other,areaUnderReceiverOperatingCharacteristicCurve
Advantage,betterOutcomeWithGoodNegativePredictiveValue
Other,alcoholConsumption
Other,planning
Other,metastasectomy
Other,182Percecnt
Survival,colonyFormation
Other,breastCancerPatientsWith1-2PositiveSlnspatientsWithBreastCancer
Other,crucialRole
Other,staining
Other,rituximab
Other,descriptiveStudy
Other,moreEasilyHypomethylated
Other,inNearFutureContribute
Other,cnvData
Other,mutationalStatusBesidesFamilyHistory
Other,scan
Other,worldwide
Other,an
Technique,control
Other,mainlyPostmenopausalWomen
Other,soFarHasMainlyAssociatedWithMutationsInBrca1
Other,Identification
Other,lastFollow-upTime
Other,surgicalImplantationReconstruction
Mutation,rs5743810
Disease,ductalCarcinoma
Other,clinicalSettingOfPreviouslyVagueDiagnosisInImaging
Other,peripheralBlood
Other,framework
Mechanism,associationBetweenPreviousCervicalCancerScreeningInBreastCancerScreening
Other,anti-apoptoticEffectsOfEstradiol
Other,over-represented
Other,responsible
Other,adherenceToEhtAmongBreastCancerPatients
Gene,VAP-1
Other,ctcCounts
Other,leastAbsoluteShrinkage
Township,thenLinkedToTownshipFemaleBreastCancerIncidenceRateIn2000s
Other,precision
Other,timeOfTheirAppointmentwithDoctor
Other,third-lineTreatmentForAdvancedTriple-negativeBreastCancerthisRetrospectiveStudy
Other,Isolation
Other,significantlyAssociated
Other,vap-1Staining
Other,performedInFemaleParticipantsWithBreastCancerFromJune2015ToDecember2017
Cell,cellMigration
Other,understand
Other,differentStudies
Other,greatPotentialInDiagnosisTherapyOfCancers
Other,prognostic
Care,cancerCareNetwork
Other,proliferationOfCells
Other,urgentlyDeveloped
Care,intervention
Other,er-positiveBreastCancer
Other,hugeVolumes
Other,ovarianCancer
Disease,RDD
Other,obstetricians
Other,reducedBaselineLvef
Other,FT
Other,non-sentinelLymphNode
Other,significantlyDecreased
Other,treatedWithIntraperitonealInjectionFor30Days
Other,Mammography
Other,preclinicallyTams
Disease,breastCancerWisconsin
Other,defectStudies
Other,excision
Other,mda-mb-231Cells
Susceptibility,researchLight
Other,theirBeliefsRegardingCancerCausation
Other,mostCommonMalignantTumor
Other,murineMonoclonalAntibodies
Other,15Percecnt
Other,22Patients
Other,us
Other,23Studies
Other,edition
Other,postoperativeComplications
Other,differentPatientRaces
Township,accurateViewOfStateOfMetastasesToAxillaryLymphNodes
Other,womenOfReproductiveAge
Resistance,activity
Other,2-3Years
Other,surgicalOptionsIncludingPreservationOfNippleAreolaComplex
Radiotherapy,neoadjuvantChemotherapyWithHerceptin
Other,chinesePublic
Other,noninvasiveImaging
Other,otherDietaryRecommendations
Other,magneticResonanceImaging
Protocols,protocols
Other,differentStages
Other,localTherapy
Other,535941Survivors
Other,largeCells
Other,1Year
Other,howeverMuchLower
Other,osteopontin-750Accumulation
Other,adulthood
Other,personalGoal-setting
Other,associated
Other,bpeLevels
Other,times
Other,approximately75PercecntOfBreastCancers
Other,doxUptakeByCs/bio-mof
Other,morphologicalDifferentials
Other,uncover
Other,youngWomen
Other,Spouses
Other,alternativeToFrozenSections
Other,commonCancerTypes
Symptom,evidence
Biopsy,sentinelNodeBiopsy
Exposure,coxModel
Other,we
Other,twoUncommonCasesOfDelayedBreastCancerRelapses
Other,clinicalPractice
Other,theirParaffin-embeddedTissues
Other,potentialBiomarkerForCancerDiagnosisThanMrnaBiomarkers
Other,decreasedExpression
Other,influences
Other,proposed
Other,Stem-likeCells
Other,only44Percecnt
Cell,canCategorizedIntoSubtypesOfLuminalA
Other,effectiveDiagnosisOfBreastCancer
Other,life-threatening
Other,haveAssociated
Other,spindleCells
Other,at25HPost-injectionGreaterInTumorBedThanInKidneyRespectively
Other,subsequentMalignancies
Other,mostCommonCancer
Survival,releaseFromSerumStarvationInMcf-7Cells
Hazard,riskOfDevelopmentOfGliomas
Other,miR-511
Other,this
Other,operablePatients
Other,capabilities
Other,disadvantages
Other,optimalTherapeuticTargetForPatientWithAdvancedBreastCancer
Other,chronic
Vitro,infraredFluorescentImagingInTripleNegativeInVitro
Other,significantlyReduced
Disease,maleBreastCancer
Other,sequencing
Other,mir-511Expression
Cytology,aspirationCytology
Cell,panelOfCellLinesWithDifferentPhenotypes
Other,clinicalOutcomesDiffer
Other,role
Other,needForAwarenessOfMimicsOfBoneMetastasis
Other,typicalWoman'sDisease
Other,variousRadiologicalChangesLeadingToDiagnosticChallenges
Other,nf-krab-inducedIncreasedExpressionOfCcnd1
Other,secondaryLymphedema
Other,averageOf425Â±496Ctcs/2Ml
Other,approaches
Other,postmenopausalWomenWithDevelopmentOfBreastCancer
Other,Demographics
Other,retrospectiveStudyOfWomenTreatedWithTrastuzumabForHumanEpidermalGrowthFactorReceptor2BreastCancerAtMayoClinicBetweenJanuary12000
Other,breastCancerCases
Other,screening
Acids,omegaFattyAcids
Other,cancerFibroblasts
Other,traumaticNeuroma
Other,irregularHyperintenseLesion
Other,possibleCorrelationsWithClinicalStatusIncludingAge
Other,place
Hazard,treatmentOutcomePrediction
Other,epigeneticAberrations
Other,mortality
Strategy,inWorkSynthesizedAsSystemForDeliveryOfDoxorubicinInTreatmentOfBreastCancer
Other,643Percecnt
Other,expressedSeparately
Other,ORR
Other,Follow-up
Other,dnaMethylation
Other,higher-qualityImaging
Susceptibility,theirHealthBehaviours
Other,recognizedAsCtcIn1Of15HealthyBloodSamples
Quantification,feasibleInProperlySelectedCasesWithAsymptomaticNeuromasAfterAccurateTissueSampling
RNAs,longNoncodingRnas
Other,context
Other,axillarySurgery
Other,11Days
Other,chances
Other,richSpectralFeaturesOfPhenyboronicAcid-basedNanoprobe
Other,proposedMethod
Quantification,successfulQuantificationOfCa15-3InSerumSamplesFromCancerPatients
Other,pCR
Other,normalTissues
Exposure,zebrafishTumorModel
Other,breastCancerGrading
Glycosylation,glycosylationOfMembraneTypeMr
Other,cross-sectionalCategories
Exposure,regressionModel
Other,high-resolutionImages
Other,challengingProblem
Other,combination
Other,one-waySensitivityAnalyses
Other,ronReceptorTyrosineKinase
Other,independentPrognosticFactor
Other,consensus
Other,evenLessFrequentComplication
Other,large-scaleStudies
Other,Cholecystectomy
Signature,key
Other,performedFromInceptionToJanuary312018
Other,SpCM
Other,hasMadeInMolecularSubtypingOfBreastCancer
Disease,Tumours
Vulnerability,nsaidsExposure
Other,statisticalClassifiers
Susceptibility,antigenIdentification
Other,support
Radiotherapy,shorterRadiotherapyRegimens
Other,7581StageI/iiaCases
Other,type160Patients
Other,tumorSuppressorFunction
Membrane,panel
Chemical,DDE
Other,thenClassifiedBySupportVectorMachines
Symptom,qualityEvidence
Other,directTargetGene
Resistance,chemotherapyResistance
Other,patientsWithBreastCancerReceivingWithAnthracyclines
Other,represented
Hazard,20PercecntIncreasedRiskOfBreastCancerAmongCurrentHormonalContraceptionUsers
Other,cancer-relatedDeathsAmongWomen
Other,ICER
Other,tumorSuppressorFunctionOfP53InPathogenesisOfBreastCancer
Other,oftenHypomethylated
Other,trastuzumabTherapy
Chemical,baicalin
Other,fewStudies
Other,breastCancerModels
Cell,g1/s-phaseCellCycleArrest
Image,multiyearCollaborationLedByUnionForInternationalCancerControl
Technique,ourFacility
Other,accessToReceptorAnalysesInCytosolAtDiagnosis
Other,measurements
Other,alteredInHumanBreastCarcinoma
Other,confirmed
Other,diseases
Signature,medianInterval
Exposure,discovery
Other,facilitatingRole
Other,localExcision/lumpectomy
Membrane,membraneTypeMr
Other,use
Toxicity,increaseWithNumberOfSprays
Other,foundInPcosCohortThanInComparisonCohort
Other,associationsOfFactorsWithLocoregionalAtDiagnosis
Other,therapy-relatedConditionsDuringBreastCancerSurvivorship
Parameters,similarExperimentalParameters
Other,pcrResults
Other,womenWorldwide
Cell,CellLines
Other,promisingTherapeuticTargetForBreastCancer
Targets,novelTherapeuticTargetsFor
Other,potentialTarget
Other,remarkableImprovements
Other,copyright
Mechanism,roleOfPdgf-b/pdgfr-betaAxisInRareTypesOfBreastCancers
Other,moreAdvancedStagingAtDiagnosisInWomen
Hazard,decreasedRisk
Disease,overallSurvival
Other,occultBreastTumors
Other,of121Patients
Symptom,evidenceForbenefits
Other,differentDetectionRates
Other,significantlyHigher
Image,correspondingHistologyImage
Other,textureAnalysis
Other,late-stage
Other,therapies
Other,100Patients
Other,robustSynthesisMethods
Other,dependent
Vivo,selectiveAccumulationOfFluorescentOsteopontinInVitroAndInVivo
Cell,canStarted
Advantage,relativelyGoodPrognosisWith5YearOverallSurvivalOf88Percecnt
Other,water
Subtype,differentSubtype
Other,first-lineTreatment
Other,developmentOfBrainCancers
Other,grafts
Other,throughOptimizationTestsChosenAsOptimalConditions
Other,observations
Other,radiomics
Other,univariableLogisticRegressionModels
Other,643PercecntWithSignificantDifferenceBetweenWhites
Other,inconsistentResults
Other,50PercecntRelapsedTissues
Other,mastectomizedWomen
Other,breastCancerIncidence
Paraneoplastic,mostLikelyParaneoplastic
Other,humanChorionicGonadotropin
Other,only1ulOfSerumSample
Other,11BreastRadiologists
Other,gtpaseInBreastCancerCells
Other,slnMetastasis
Other,fastDayBefore
Other,ourPreviousWorkRegardingToPropertiesOfPluronicsWithDifferentPhotosensitizerForPhotodynamicTherapy
Other,arms
Other,macrophage-targetedTreatmentStrategies
Other,speed
Other,perturbation
Other,thereforeAdministered
Other,breastMetastasis
Other,hasUsed
Other,willDifferent
Other,they
Other,intravenousAdministrationOfOsteopontin-750Probe
Other,deathInWomenWorldwide
Other,fxyd3Amplification
Other,analyzed
Other,mir-193b-3pIdentifiedAsRegulator
Other,haveBackboneOfSuchEnormousStridesOfAu
Other,Israel
Other,stratifyingForAge
Other,preclinicalModels
Presentations,rarePresentations
Other,probablyTranscriptionalActivation
Quantification,whole-tumorSamplingOfDiseaseBurden
Survival,survival
Other,preservationOfBiomarkerExpressionInOldFfpeTumour
Cytology,histology
Other,images
Hazard,riskOfBreastCancerInAdulthood
Other,correspondingCohort
Other,earlyBreastCancer
Other,prevalenceOfobesityOf277Percecnt
Other,lowLevel
Other,needForAnalysisOfMetastaticTissuesAtRecurrence
Other,eConcentration
Other,previousStudies
Other,TAM
Other,adjustedProportion
Technique,breastCancerControlEffortsForIdentification
Other,cruciferousVegetables
Other,symptomaticWomen
Other,infiltrationSimilar
Other,exercise
Other,healthInitiative
Other,furtherUnderstanding
Susceptibility,danger
Other,forThoseWithNormalLvef93Percecnt
Other,negativeMargins
Other,relationship
Other,505PercecntOfAnalyzedCases
Other,highlyExpressed
Hereditary,mustAddressedDuringCancerGeneticCounselingConsultations
Other,interimStageInProgressionFromDcisToInvasiveBreastCancer
Other,P
Radiotherapy,neoadjuvantChemotherapyGroups
Other,authors
Other,highestIncidenceAmongMalignanciesDiagnosedInWomen
Mechanism,humanBody
Other,haveDiscovered
Disease,chorea
Other,detectedByImmunohistochemistryInApproximately70PercecntOfInvasiveBreastCancers
Cell,cellCycleRegulators
Other,mistaken
Correlation,expectedInverseCorrelation
Radiotherapy,practicalImplicationsOfOngoingChemotherapy
Care,care
Other,rolePlayedByPdgfFamilyMembersInNormalDevelopmentOfBreastTissueDespiteItsPotentPro-lymphangiogenicEffects
Other,differentials
Disease,death
Other,methylationStatus
Other,interpretation
Other,particularEmphasisQuantifying
Image,imageSegmentation
Cell,variousCellularProcessesCellCycleRegulation
Other,GTPase
Other,humanErrors
Other,confirmedUnilateralHer2-positiveBreastCancer
Strategy,potentialTreatmentStrategyForEndocrine-resistantBreastCancers
Other,expected
Other,strongIndependentPrognosticFactor
Disease,heartFailure
Other,aberrances
Biopsy,biopsy
Toxicity,numberVariants
Other,pathologicEvaluation
Other,search
Other,weak
Other,probe
Other,portugueseInstitute
Other,retrieved
Other,905Percecnt
Other,case
Other,betterUnderstandingOfRisksAssociatedWithM
Image,itsHistologicAppearance
Susceptibility,thereforeHasAppliedToEarlyIdentification
Other,autopsyStudies
Other,weight
Other,successOfSymmetricPositiveDefiniteMatrices
Other,handheldProbeCapable
Other,amount
Other,menopausalHormoneTherapy
Other,subsequentCancerCounselingOfFemaleSurvivors
Variants,pathogenicVariants
Other,reality
Other,pathogenic
Other,CXCR4
Mechanism,barrierFunction
Other,complementaryApproaches
Other,highlyEffective
Other,non-coverage
Other,theirAbility
Other,thatInMabaGroup
Gene,HER2
Other,testing
Phenotype,structureChanges
Other,mainObjective
Technique,imagingTechnique
Quantification,quantification
Other,additionalIndicator
Other,twoGroups
Other,haveObserved
Other,significantCausativeGenes
Other,evidencedByIncreaseInContrastAfterInjection
Other,label-freeDetection
Other,solubleSt-2Level
Advantage,tumorSizethePositivity
Other,carrier
Other,ultrasound-guidedDiffuseOpticalTomography
Other,baGroup
Other,disseminatedDisease
Chemical,estrogens
Hazard,lowRiskLesions
Resistance,potentialApplicationForDiagnosisOfCancerInFuture
Surgeries,complexSurgeries
Other,inHumanBreastCancerHasReported
Other,Herceptin
Technique,technique
Other,CNVs
Other,carbonDioxideLaserTechnology
Other,lung/bronchusMalignancies
Cell,cell
Paraneoplastic,paraneoplasticAntibodyPanel
Other,WHI
Other,importantlyCouldPotentialDiagnosticBiomarkerInEthnicPopulation
Other,commonComplaint
Other,meanwhileBetterThanInCapecitabineGroup
Other,suchSymptoms
Other,experts
Other,occurrence
Other,shouldStaged
Other,cancerDiagnosis
Other,toEndDevelopedWithDrugToAntibodyRatioOf329
Other,period
Other,cytologicalExamination
Other,ourPatient
Other,commonMedications
Contraception,hormonalContraceptionUse
Other,well-established
Other,dependentOnRigorousPathologicEvaluationOnAdministrationOfTreatmentDictatedByTumorBiology
Other,infiltrativeLesion
Other,secondSurgery
Other,improvedDetection
Hazard,subjectiveRisk
Other,couldConsidered
Other,65-year-oldFemale
Disease,cancer-relateddeaths
Neoadjuvant,administrationOfNeoadjuvant
Correlation,correlationCoefficientOnMetabricTrainingSet
Other,nano-biosensor
Other,connected
Other,mainContribution
Other,tested
Other,treatmentTherapy
Other,mab1e3
Other,20BreastCancerPatients
Other,betterAccessToAtertiaryCancerCenter
Other,linked
Other,414Percecnt
Resistance,conflict
Other,illiterate
Other,postOperativeAssessment
Other,imagingInvestigations
Other,analysisOfLncrnaExpressionProfiles
Other,conventionalTreatmentProcesses
Other,longerPeriods
Technique,60ControlPatients
Other,plasmaLevels
Other,hybridCultures
Other,higherProportion
Other,willUsedAsReferences
Other,termsOfKyotoEncyclopediaOfGenes
Other,RON
Correlation,correlationCoefficient
Other,ca15-3ByCmia
Other,centralDenmarkRegion
Other,vitalRoles
Other,luciferaseReporterAssay
Radiotherapy,timingOfChemotherapyForBreastCancersWithDifferentMolecularBackgrounds
Other,secondDecadeAfterDiagnosis
Other,massSpectrometry
Other,cells
Other,shouldCo-managed
Other,withandControllingForTreatmentDelays
Other,volumes
Resistance,tamoxifenResistance
Other,0.029
Other,protective
Other,tumorImaging
Other,moreLikely
Other,5Of10Patients
Exposure,reportOnPerformanceOfBayesClassifiersLikeTreeAugmentedNaiveBayes
Other,treatmentStrategies
Other,diagnosisOfEstrogenReceptor
Signature,responseRate
Other,earlyStageDiagnosisOfTumors
Survival,patientSelectionForNon-pcosReferenceCohort
Other,increases
Signature,lifestyleModification
Other,urgent
Other,howeverSwitched
Other,futureInterventions
Other,inConclusionDownregulatedInBreastCancer
Variants,pathogenicVariantsInBrca1/2
Other,tumor-to-backgroundRatio
Other,mostNondestructiveTests
Other,neglected
Other,analyzing
Other,criticalScientificBase
Other,patients'Prognosis
Other,usStandardization
Other,metastaticDisease
Advantage,importantCopingResource
Gene,PCDH10
Other,9398
Other,breastCancerDetectionMethod
Other,pureDcis
Other,breastCancerGenes
Other,characterized
Other,primaryTumours
Other,fisherAnalysis
Other,subtypes
Technique,controlTrial
Other,lessVisits
Other,westernBlotAnalyses
Other,neonatalOfRetrospectiveCohortOfPregnantWomenWith
Susceptibility,improvementInClassificationOfMalignantLesions
Other,described
Hazard,increasedRiskWithUseOfLevonorgestrelIntrauterineSystem-bothOfPotentiallyImportantFindings
Hazard,peakInRecurrenceRisk
Other,femalePatient
Other,advances
Other,major
Other,australianSynchrotron
Susceptibility,moreResearchLight
Other,outcomes
Other,alexnetModels
Other,receptorActivator
Exposure,itsPerformance
Other,miR-204-5p
Other,bt549Cells
Other,events
Survival,itsMinimalSilverIonReleaseProfiles
Radiotherapy,chemotherapy
Other,pathologists'Awareness
Other,craniotomy
Other,samples
Other,90Percecnt
Other,inStudyDevelopedByCell-selex
Other,sexualStigmatizationOfM
Other,breastTumorMicroenvironment
Other,factorsRelatedToPresenceOfMetastaticDiseaseAtDiagnosis
Care,theory-basedIntervention
Susceptibility,changesToIntimateIssuesIncludingSexualHealth
Other,her2/hrTripleNegativeTnmStages
Other,diagnosis
Disease,invasiveDuctalCarcinoma
Other,treatmentMoreAccessibleToBreastCancerPatients
Exposure,limitedPerformanceForWomenWithDenseBreasts
Survival,comparisons10-yearSurvival
Other,veryComplexDisease
Other,rare
Other,282Patients
Other,Individuals
Other,theirOriginallyTargetedPopulationsOfBreastCancer
Other,roleOfSupportOfferedByVirtualCommunitiesToBreastCancerPatients
Care,standardOfCareForBreastCancer
Other,associations
Other,miRNAs
Mechanism,alarm
Other,diagnosisAccuracy
Other,causes
Other,immunocaptureOfMarker
Other,uptake
Other,Data
Atypia,nuclearAtypia
Other,heterogeneousPopulationsOfCellsWithHierarchicalOrganizationDrivenByCancerStemCells
Other,knownHeterogeneousDisease
Other,fisherDiscriminantAnalysis
Other,histopathologicallyProvedBreastTumors
Other,westernizedCountries
Other,values
Other,stromalExpression
Other,importantContributors
Other,mustIndividualized
Other,satisfied
Other,dcisWithMicroinvasion
Other,betterDiagnosticAccuracyThanFfdm
Other,tissueMicroarray
Other,criticalScientificBaseForPrecisionMedicineInBreastCancer
Other,84Patients
Other,invasiveDiseaseretrospectiveAnalysisOf219Cases
Other,normalSamples
Other,guidedImagery
Susceptibility,positiveChangesInTheirHealthBehaviours
Other,ourResults
Hazard,summaryHazardRatios
Other,differentialDiagnoses
Advantage,goodCorrelationBetweenErAnalysedWithCytAtDiagnosisAnalysedWithIhcInArchivedFfpeTissueFromSameTumour
Other,hasFocusedOnTumourCellsPrimarily
Other,unusualCaseOfPtosis
Other,sparseCombinationOfRiemannianDictionaryAtoms
Symptom,effectOfBaicalinInBreastCancer
Other,type
Other,betterPrognosis
Biopsy,rightMastectomyWithSentinelLymphNodeBiopsy
Strategy,mightPromisingTherapeuticStrategyForHormone-therapyRefractoryEr
Other,issues
Other,radiologicalSignsOfMalignancy
Other,adhesionProtein-1
Other,newerDrugDeliveryStrategies
Other,classifiers
Other,trastuzumab/pertuzumab/taxane
Mechanism,association
Other,highCoverage
Other,synthesized
Disease,cancer-relatedDeath
Other,mechanisms
Other,prognosis
Other,imagery
Other,patients'MedicalRecords
Other,hospitalFromJanuary2016ToFebruary2017
Mechanism,associationBetweenPost-diagnosisUseOfLow-doseAspirin
Other,percecntRelapsedTissues
Hereditary,differentGeneticProfile
Other,mir-511Overexpression
Other,documented
Other,subset
Advantage,osAdvantage
Cell,canOnlyDiagnosedOnPresentationOfSymptoms
Hereditary,multipleGeneticAberrances
Other,symptomaticHeartFailure
Quantification,successfulQuantification
Other,clarify
Other,fluorescenceImaging
Hazard,clinico-pathologicalRiskFactors
Other,severalPatients
Other,pearson'sR
Other,specificFoodRecommendations
Other,nowAlsoWidelyUsed
Other,unnecessaryFollow-upVisitsForWomenWithVeryLowRisks
Other,120BreastCancerPatients
Other,breastCancerAged
Other,periods
Symptom,cell-killingEffectInTriple-negativeSubtypeMda-mb-231Cells
Other,training
Other,independent
Strategy,potentialTreatmentStrategy
Other,shapes
Gene,STAT1
Mechanism,mechanism
Other,RL
Other,32620MatchedPatientsWithoutPcos
Other,qualityOfLife
Symptom,oftenWellScrutinisedByPathologistsForEvidenceOfMetastaticCarcinomaAsImportantPrognosticParameterInStandardSetting
Other,10.1
Other,visualizedTheranosticsOfTumors
Other,isReplaced
Other,initiationOfPromptTherapy
Other,collisionTumorWithBreastCancerMetastasis
Other,vitalRole
Other,henceMainlyBased
Other,tumorigenesisOfBreastCancer
Other,3-timeAssessments
Other,noted
Other,bronchoalveolarCarcinomaUnrelatedToKnownMetastaticBreastCancer
Other,misdiagnosis
Other,Cell
Other,five
Other,SE
Other,random-samplingMethod
Other,lymphNodeMetastasisInPatientsWithBreastCancer
Other,SVM
Other,percecntConfidenceIntervals
Other,consequencesForSurvival/relapse
Other,important
Other,objectives
Other,developmentOfPolicies
Other,positiveChanges
Other,CMIA
Other,accurateDiagnosisOfBreastCancerSubtypes
Other,iraqiWomenWhencomparedToWesternWorld
Other,firmlyPlaceWithRecentTrendsTowardDecreasedRatesOfRe-excision
Other,alsoShaped
Other,mostEuropeanCountries
Other,moreRefinedStratificationThanAnatomicStageAlone
Other,annexinVStaining
Other,treatedWithCapecitabineMonotherapyAsThird-lineTherapy
Vulnerability,nsaidExposure
Other,severalOtherGenes
Strategy,revisionsOfAjccBreastCancerStagingSystem
Other,inPresentStudyPerformedFor9Features
Other,concentrationsOfVegf-aInComparisonToCa15-3InBreastCancer
Other,DPV
Other,widelyUtilized
Other,biologicalSubtypes
Other,largeBreastCancerTissueMicroarray
Resistance,thusWouldCrucialForApplicationOfPreventiveStrategies
Other,meanTime
Other,postAssessment
Other,assessment
Quantification,multidimensionalScaling
Other,presented
Other,findings
Other,maintainedBreastCancerDatabase
Other,normalDucts
Other,R
Other,trastuzumab
Other,treat
Other,secondLargestHmo
Other,99Percecnt
Other,10Mg/kg
Other,logisticregressions
Other,consistent
Other,femalePatients
Other,supplements
Other,mutationRatio
Other,pLessthan
Susceptibility,emergingPublicHealthProblemInLowCountries
Other,estrogenReceptor-alpha
Other,12-15Percecnt
Cell,weakToStrongReactivityToOtherCellLines
Other,typicalWoman
Other,sixteenRegionsOfKazakhstan
Other,bevacizumab-relatedCardiotoxicity
Biopsy,sentinelLymphNodeBiopsy
Species,Patients
Other,ductalCarcinoma
Other,smallerMyeloperoxidase
Toxicity,number
Susceptibility,nippleInvolvement
Other,Resurgery
Other,archivedFormalin-fixedParaffin-embeddedTissue
Other,1722Comments
Disease,breastCancerStaging
Other,managementOfTumour-relatedSymptoms
Other,changes
Sites,sixGlycosylationSites
Other,suggested
Other,most
Other,recommended
Other,shouldProcessed
Hazard,theirRisk
Other,urgentlyNeeded
Membrane,atrophiedVaginalMucosa
Other,breastCancerScreeningProgramme
Other,Residents
Other,coverageRates
Other,outliers
Gene,Protocadherin-10
Other,variousNon-pharmacologicalAdjuvantTherapies
Other,mostCommonCancerInWomen
Other,Wilm
Other,subsequentLung/bronchusMalignancies
Phenotype,roleOfImage-basedTextureFeaturesAsNoninvasivePrognosticBiomarkers
Other,totalGroup
Other,enhancerRegions
Susceptibility,associationsOfPhysicalActivityInGlobalHealthInBreastCancerSurvivors
Other,roleOfPrimaryCaregiver
Other,insufficient
Other,kaplanMeierCurves
Other,49Patients
Other,youngerBreastCancerSurvivors
Other,cases
Other,51Days
Other,pcosGroups
Other,pureDcisInClinicopathologicCharacteristics
Other,Researchers
Other,advancedBreastCancerBearingMutationsInGenesInvolvedInPi3k/ark/mtorSignalingPathway
Gene,FXYD3
Other,ssdnaAptamerMf3
Other,S
Other,closelyAssociated
Care,scalableIntervention
Vulnerability,exposure
Biopsy,openBiopsyOfNodularityAttachedToPectoralMuscleFascia
Other,elusive
Other,relatedTranscriptionFactorSox9
Risk,leadingCauseOfDeathAmongGynecologicNeoplasias
Other,secondTumor
Other,molecularChanges
Other,ultrasound
Other,divided
Other,canineTumours
Other,sParticipants
Other,femalePatientsWithAd
Other,missed
Other,diagnosticEvaluation
Other,recentDevelopments
Other,immediateUnmetNeedInClinicalPractice
Image,activeNon-participants
Other,seen
Other,development
Other,moreoverRemarkablyIncreased
Other,Computer
Other,hasApplied
Disease,boneLoss
Image,caseOf68-year-oldCaucasianFemaleWithFamilyHistoryOfCancer
Other,delay
Other,understandingOfEmergingConceptsOfTumorBiology
Other,mPatients
Other,analysisInvestigate
Cell,canExtended
Other,news
Exposure,excellentPerformance
Other,post-NAC
Other,qualitativeApproach
Other,postponementVisiting
Other,histoneModifications
Disease,PCOS
Other,differentBreastCancerMolecularSubtypes
Parameters,morphologicParameters
Other,diagnosisOfAcuteCoronarySyndromes
Other,surveillanceData
Other,frequentLargeSingleGiantCellsWithNucleiLocatedPredominantlyWithinSupsularSinuses
Other,similar
Other,esr1SomaticAlterations
Other,DCR
Other,offered
Other,totalOf121Patients
Other,2=
Chemical,Estrogen
Other,currentUsersOfLongerDuration
Other,expressionOfCxcChemokineReceptor-4
Exposure,nomogram
Other,moreAggressiveBiologicalNatureThanPureDcis
Other,38-year-oldFemale
Other,mirnaExpressionProfiles
Other,recentYears
Hazard,coxHazardRegressionModels
Other,splenicLymphocytes
Other,significantlyProlongedMedianPfs
Other,clinicalVisits
Other,complaint
Other,0.001
Survival,survivalRates
Other,proteinExpression
Other,significance
Other,Development
Other,classified
Exposure,performanceEvaluation
Other,mistakenDiagnosisOfMalignancy
Vitro,bindingToBreastCancerCellsInVitro
Other,separateClassificationModels
Other,tumor-1
Other,fewerInstancesOfSpreadToLungs
Other,switched
Other,known
Other,nondestructiveTesting
Hereditary,geneticMutation
Other,annualMammographyAssociatedWithEchography
Care,mustIndividualizedWithEmphasisOnOptimalCareOfMother
Hazard,riskFactorsOfLviByMultivariateAnalysis
Exposure,potentialImpact
Membrane,antibodyPanel
Other,assessedinclusionCriteriaForEnrolment
Other,processing
Other,thenAdded
Other,stigmatization
Other,importantComponent
Other,howeverMoreDrastic
Other,limitedLiterature
Other,histopathologicalreports
Other,researchers
Other,reference
Other,It
Other,CNN
Toxicity,minimumToxicityToNormalCells
Hazard,significantHigherRisk
Other,inCaseReportTypicalOfAdvance
Other,program
Other,tissueDiagnosis
Targets,targets
Hazard,eventHybridizationOfMirna-21Biomarker
Other,serious
Other,mostFrequentMalignancy
Other,suutaneousBreastTumor
Species,participants
Other,delivery
Other,inAdditionFurtherConfirmedInEarlyStage
Exposure,assessmentOfImpactOfAdvancesInDiagnosisOfPatientsWithBreastCancer
City,almatyCity
Other,historyPhysicalExamFindings
Other,patient'sTumorBurden
Other,sleepDisturbances
Other,sensitiveNano-genosensor
Heterogeneity,heterogeneity
Factor,factorAnalysis
Susceptibility,globalHealth
Other,nanocarrier
Other,cpgIslands
Other,patientsWithHumanEpidermalGrowthFactorReceptor2
Other,Depletion
Other,differentPhotosensitizerForPhotodynamicTherapy
Other,issuesOfExistingContrastAgents
Disease,tumour
Hazard,asResultAreUsed
Signature,haveDescribedInResponseToNeoadjuvantChemotherapyParticularlyInAssociationWithHerceptinTreatment
Other,unilateralBreastCancer-relatedLymphedema
Other,contexts
Other,breastCancerMolecularSubtypes
Care,concernForExistenceOfCancerCellsInGrafts
Other,veryRareClinicalEntityWithOnlyFewCasesHavingReportedToDate
Other,fastRate
Other,nondestructiveTests
Other,NLR
Other,emphasis
Other,theResulting
Other,dual-phaseContrast
Other,er-positive/humanEpidermalGrowthFactorReceptorType2-negativeBreastCancers
Other,despiteTheirRarityShouldConsidered
Other,twoImagingIndexes
Other,Ontario
Other,patientsWithMetastaticBreastCancer
Signature,diagnosisOfResponseToTreatment
Other,significantAdvances
Other,overnight
Other,pcrThanWomenWithHr-positiveTumors
Other,preciseToolForTargetedTreatmentOfCancerIncluding
Cytology,fine-needleAspirationCytology
Other,detectedThroughScreeningThroughSigns
Other,kind
Other,highAmountOfDox
Other,highDetectionRateOfSentinelLymphNodeComparableWithRiMethod
Other,life
Other,secondary
Other,importantPotential
Other,firstOrganisedRound
Other,therapeuticTargetForPotentialTreatment
Other,pairedUntreatedPrimaryTumor
Other,medications
Other,moreSatisfiedWithTheirCosmeticResultsThanThose
Hazard,riskForRecurrence
Disease,brainMetastasis
Other,normalCardiacFunction
Other,markedlyUp-regulated
Other,growthOfFbxo22-depletedEr-positiveBreastCancers
Other,aptamerMf3
Other,mriImaging
Advantage,willLeadToMortalityReductionsWithoutUsualScreeningHarms
Other,iU22
Other,termsOfClassification
Other,understanding
Other,mortalityRates
Other,Access
Technique,novelPowerfulTechnique
Other,breastImagingModality
Other,betterOs
Other,bilateralTotalMastectomies
Other,expressionOfRrm2
Other,filipinoWomen
Other,factor-1Scores
Other,186S
Toxicity,cytotoxicityOfFreeDoxMolecules
Other,chronicDebilitatingLifelongComplication
Other,themVeryDifficult
Other,comprehensiveSearch
Other,irregularHyperintenseLesionInT2InLeftParietalRegion
Other,kaplan-meierCurves
Other,distinct
Other,CLB-Pt-CLB
Radiotherapy,neoadjuvantChemotherapy
Other,patientEducationIdentification/reportingOfSideEffects
Other,her2-positiveInvasiveDuctalCarcinoma
Other,demonstrate
Other,included.When
Biopsy,stereotacticWire-guidedBiopsy
Other,mostInvasiveDisease
Other,higherRisksOfTreatmentDelays
Other,conventionalBafifty-fivePatientsUndergoingViaMabaForPtmc
Other,complexTreatmentAlgorithms
Other,mayDistinctEntity
Disease,cytotoxicity
Other,inAssay
Other,inCaseSecondaryToProximalBronchialObstruction
Other,matched
Other,novelTargetedTherapeuticOptions
Other,Kenya
Other,incidence
Image,heterogeneousDiseaseInItsHistologicAppearance
Mechanism,associationOfToll-likeReceptor6WithBreastCancerInSaudiArabianWomen
Other,brainMetastases
Other,henceMajorResearchGoal
Other,MortalityRates
Other,dataAnalytics
Other,utility
Other,twoLargeBreastCancerDatabases
Other,relation
Other,switch
Other,alsoUsed
Other,unclear
Other,diet
Other,diagnosisOfGallbladderMetastasis
Other,substantialDiscordancesBetweenPrimaryTumors
Other,itsExpressionLevel
Other,estimated
Other,40
Other,positiveSln
Other,cohortStudy
Other,Immunohistochemistry
Other,186Pathology-provenS
Other,therapeuticAdvantagesParticularlyInCaseOfPremenopausalBreastCancers
Other,electiveCholecystectomyForSymptomaticCholelithiasis
Other,elusiveToTargetedTherapies-theTriple-negativeBreastCancer
Other,expressionProfileOfNek6In133BreastCancerSpecimens
Other,independentPrognosticPredictor
Hazard,riskFactor
Other,particular
Other,detailedRoles
Vivo,fluorescenceImagingExVivo
Other,generalPopulation
Neuromas,breastNeuromas
Other,significantlyYounger
Other,achievedForHer2Status
Other,forefront
Other,thematicAnalysis
Hazard,poorerOutcome
Other,haveReportedForFirstTimeInCaninesInStudy
Other,patientsOnAromataseInhibitors
Other,jak-statPathway
Other,usuallyAssociated
Other,howeverElusive
Other,numerousGene-expression-basedPrognosticSignatures
Other,massInPosteriorFossaOfBrain
Other,undiagnosed
Other,eighthEdition
Other,pleurodesisForMalignantPleuralEffusion
Other,likelihoodOfDetectionOfMicrometastases
Hereditary,inConclusionMajorHereditaryBreastCancerGenesIrrespectiveOfAgeAtDiagnosisInJapaneseWomen
Other,whereDeveloped
Other,robustTechnology
Other,significantlyCorrelated
Other,chapter
Other,mean
Other,simulatedBreastCancer
Radiotherapy,chemotherapyGroups
Chemical,melatonin
Other,identifiablePcrResults
Other,average
Other,surgery
Other,breastCancerPatientsSerum
Other,workflowConsistingOfImmunoaffinityPurification
Other,independentlyAssociated
Other,single-cellWhole-exomeSequencing
Other,thereforeApplied
Other,importantProblem
Other,breast
Other,spouse
Gene,HR
Other,133BreastCancerCases
Other,0.32
Other,obstetrician
Signature,interval
Other,capecitabineRegimenAsThird-lineTreatmentForAdvancedTriple-negativeBreastCancer
Other,team
Other,12404Patients
Toxicity,considerableNumber
Other,diagnosticRole
Other,developmentOfNewDrugs
Other,cutoff
Other,twoScales
Other,rareTumor
Other,awareness
Other,976PercecntSensitivity
Other,quantitativeRealTimeFluorescencePolymeraseChainReaction
Other,m
Other,hasPut
Other,medianAge
Other,westernBlotAnalysis
Other,enhancedPossibility
Other,controversial
Other,alive
Other,erCscs
Other,12SampledWomen
Other,mostPrevalentMalignancyAmongWomenAroundWorldAreDiagnosedYear
Other,bromideAssay
Mechanism,contraceptiveUse
Other,oftenRelated
Cell,cancer-relatedEventsIncludingTumorCellMigration
Other,subsequentMalignanciesForLung/bronchusCancerWith13PercecntSurvivorsSufferedFromSubsequentMalignancies
Other,enrolled
Other,428BreastCancerPatients
Other,improvedDiagnosis
Presentations,rareClinicalPresentations
Other,those
Other,only35Cases
Other,.014
Other,investigated
Other,hasFocused
Other,amplifications
Other,clinicalCharacteristics
Other,conventionalX-rayMammography
Other,pregnancy
Other,leftParietalRegion
Other,totalHemoglobinConcentration
Other,otherSubtypesOfBreastCancer
Other,lymphocytes
Other,manyPatients
Other,harmfulorHarmlessTissues
Other,RRM2
Other,followedFromDateOfFirstDiagnosisOfAdToEndOf2013
Other,osteopontinPeptide
Other,10-foldCross-validation
Other,thoseWithHr-positiveTumors
Other,referral
Other,rs5743810ProAllele
Other,oestrogenReceptorPositiveIn58PercecntOfCasesPositiveIn62Percecnt
Other,ourLiteratureReview
Cytology,intraoperativeScrapeCytology
Hereditary,hereditaryCausesOfChorea
Other,tumorGrowthInExperimentalModels
Other,17MillionPeople
Other,statisticallyCorrelated
Care,fearOfPartnerLoss
Long-term,differentLong-termSurvival
Other,resources
Other,real-worldSetting
Other,stat1RecruitmentToEralphaPromoterRegion
Other,significantlyCorrelatedWithTumorSize
Susceptibility,commonEndocrineDisorder
Other,difference
Other,theirOwnParticularity
Other,thenPresented
Other,0.003
Other,drugDeliveryStrategies
Other,population
Other,consistentMass-spectralData
Other,novelNavigationSurgery
Other,omission
Other,902Percecnt
Other,tumorBurden
Other,oftenDebated
Other,consensus-based
Other,counseling
Other,PI3K/AKT/mTOR
Other,773Percecnt
Other,regulated
Susceptibility,dryness
Other,4248BreastCancerPatients
Other,trend
Other,binding
Other,cardiacTroponins
Other,cytohistologicalComparisons
Other,manyComputerVisionApplications
Other,highSensitivity
Other,novelNear-infraredNirFluorescentProbe
Image,memorialSloanKettering-integratedMutationProfilingOfActionableCancerTargets
Other,firstTime
Other,women'sPersonalGoals
Other,promoterMethylationStatus
Glycosylation,glycosylation
Other,mostFrequentlyOccurringCancer
Other,posteriorFossaOfBrain
Other,betterResults
Other,moreoverStronglyRecommended
Other,moreRecommended
Advantage,advantage
Other,surveillancePopulation-basedData
Other,molecularBasis
Other,retrospectiveObservationalStudyOf264Her2-positiveAdvancedBreastCancer
Other,cross-validation
Other,haveValidatedByClinicalStudiesInCardiotoxicityDiagnosisInPatientsTreatedWithHighDosesOfAnthracyclinesAloneInCombinationMainlyWithTrastuzumab
Other,fbxo22-dependentManner
Other,axillaryClearance
Other,protected
Other,stageI/iiaCases
Other,Referrals
Other,ourExperience
Other,42
Other,bioimpedanceAnalysis
Other,diagnosed
Other,areas
Other,frequentCancer
Other,earlyCancerDiagnosis
Other,greatPromise
Other,useful
Disease,invasiveBreastCancer
Other,need
Other,controls
Other,adjacentNon-tumorousTissues
Other,painlessLumpInBreastAccountingFor688PercecntOfPatients
Other,independentPrognosticFactorForDfsOfEarlyStageBreastCancer
Other,pairedTumor
Other,inConclusionStronglyAssociatedWithNonparticipationInS
Other,benchmarkMethod
Other,cylindricalGeometries
Other,decreased
Other,sentinelLymphNode
Other,detectionMethod
Other,cscMarkers
Resistance,greatPotentialOfClinicalApplication
Mechanism,variousOtherCancerInHumanBody
Other,prospectiveNestedCase-controlStudy
Other,reverseTranscriptionQuantitativePolymeraseChainReaction
Other,methylation
Survival,theirSurvival
Other,decrease
Other,Patients
Other,complication
Other,recognized
Other,cross-sectionalStudy
Other,similarTendencyRelatedWithPrognosticFactors
Other,notablyDesigned
Other,effectivenessOfNationalScreeningProgrammes
Other,results
Other,mostFrequentCancerInWomenTreatedWithHormonalTherapy
Other,potential
Other,psychologicalAspects
Other,standardBiomarkerTestingByImmunohistochemistry
Signature,inMarch2014BroadcastedAsPart
Other,options
Other,statisticallySignificantValuesAt4Cells/7MlBlood
Other,comparisonCohort
Other,differentialDiagnosis
Other,spouses
Other,genes
Hazard,associatedWithBreastCancerRisk
Other,fiveGroups
Survival,progression-freeSurvival
Hazard,RiskProtection
Other,stillDifficult
Susceptibility,haveAssociatedWithNippleAreolaComplexInvolvementInPatientsWithBreastCancer
Other,95PercecntConfidenceIntervals
Other,doses
Other,differentFunctionRegions
Care,widelyAcceptedAsStandardOfCareFollowingBreastConservation
Other,agents
Other,multigenePanels-with
Resistance,panelOf25GenesInvolvedInMechanismsOfTargetedTreatmentResistanceIn16PrimaryBreastCancersDevelopedDuringTreatment
Other,little
Mechanism,patternsOfAssociationResults
Other,descriptive-analyticCross-sectionalType160FemalePatientsWasselected
Other,prognosesOfYoungMenWithBreastCancer
Other,urgentlyAdvanceImplementation
Other,5-yearResultsOfPhase3Isg23-01Trial
Other,developmentOfGraphicallyTailoredScreeningTool
Other,materialDetection
Cell,canIncluded
Care,extensiveAttentionOfResearchers
Other,extramedullaryHaematopoiesis
Vulnerability,associationBetweenNsaidsExposureInFemalePatientsWithAd
Other,firstTimeIn1984
Other,abstractDataOnTheirClinicalCharacteristics
Other,therapeuticEffectsInBreastCancer
Other,myeloperoxidase
Other,synthesisMethods
Other,functionalAssessments
Other,knowledge
Gene,MORC4
Other,essential
Other,years
Disease,breastTumor
Other,basis
Other,earlyDiagnosis
Other,tumorEasily
Survival,survivalDifferences
Other,timeIntervalsFromFirstDetectionToDiagnosis
Other,differentHistologicalAspects
Other,pregnancyFrom1959To1966
Disease,lungCancer
Disease,breastCarcinoma
Phenotype,alongsideRoutineMethodEmployedOnTexture
Other,2IndependentCohorts
Other,calculated
Other,st-2Level
Other,bilateralSalpingo-oophorectomy
Phosphorylation,phosphorylation
Other,tissues
Disease,cardiacInjury
Other,preoperativeAssessment
Other,proteinKinase
Other,capillaries
Survival,radiation
Other,increasedRonExpression
Other,potentialImportanceAsModelsForHumanBreastCancer
Other,womenInWorld
Other,overallLowOfSixCirculatingMirnas
Other,kinds
Other,her2Status
Other,undergone
Other,locoregionalDiseaseOfUnspecifiedLocation
Other,developmentOfEffectiveDrugsForTreatmentOfHormone-dependentBreastCancer
Survival,three-yearSurvivalRates
Other,mostPrevalentMalignancyDiagnosedInPregnancy
Other,incidenceRates
Other,small
Other,study'sObjectives
Other,growth
Other,prognosticStagingSystems
Other,locallyAdvancedBreastCancer
Other,clinico-pathologicalFeaturesOfMetastases
Resistance,resistanceToMultipleTypesOfTreatmentInBreastCancerModels
Other,organotropic
Other,cutoffValues
Disease,hereditaryDisease
Other,caDetection
Other,administered
Other,fibroblasts
Other,higher
Other,earlyBreastCancerDetectionSystems
Other,sensitivity
Other,bestStandardTreatmentRegimenAvailable
Other,sustainedStableDisease
Other,queried
Other,microfluidicChips
Other,importanceOfProactivelyAddressingFertility
Other,hospitalCohort
Other,pathologicalResults
Other,furtherResearch
Other,dissectionOfLymphNodes
Chemical,Baicalin
Other,BPE
Membrane,membraneTypeMannoseReceptor
Other,howeverNon-ideal
Survival,survivalPrediction
Other,required
Other,lisbonRegion
Technique,breastCancerControlEfforts
Other,relationshipBetweenStromalExpressionOfPodoplaninInInvasiveBreastCarcinoma
Other,adherenceToRecommendationWith95PercecntConfidenceIntervals
Other,fieldOfBreastCancerDetection
Other,768PercecntSamplesWithOverexpressionIn76Cases
Other,forefrontOfResearch
Other,ctcIsolationTechniques
Other,fourTypesOfBreastCancer
Survival,littleSurvivalVariance
Other,pre-operativeAssessment
Other,material
Other,youngMexicanWomen
Other,towaveletFilter
Disease,fibroadenoma
Survival,surgicalExcisionWithRadiation
Other,blackWomen
Other,DDTs
Other,injury
Quantification,periodOfObservation
Survival,metabricTrainingSet
Other,risksOfLate-stageDiagnosis
Other,sulass
Other,appropriateSequencing
Other,moreInclined
Other,follow-upSchemes
Other,compared
Other,breastCancerMetastasis
Other,neuroma
Exposure,performance
Other,metastasisFromLobularBreastCarcinoma
Other,regulationOfNras
Strategy,nirFluorescenceImagingSystem
Other,critical
Other,trastuzumabTherapyForBreastCancer
Other,bulkyHighlyTechnical
Other,China
Tumor,tumorNippleDistance
Other,networkOutput
Vulnerability,ddtExposure
Symptom,clearEvidenceForbenefitsOfTanUsageInBreastCancerClassification
Other,algorithm
Other,denseBreasts
Other,distributions
Other,adjustingForPotentiallyConfoundingFactors
Other,studies
Other,currentUtilizedHistopathologicBiomarkers
Disease,LVEF
Other,nature
Regulatory,positiveRegulatoryFeedbackLoopForFxyd3Amplification
Susceptibility,healthBehaviours
Other,personalizedFollow-upSchemes
Other,bestChancesOfCure
Other,ribonucleotideReductaseM2
Other,clinicalRecords
Other,1H
Other,expressed
Other,diagnosticUncertainty
Other,pathologistAnnotation
Susceptibility,moodOfLife
Other,f-boxProtein22
Other,widelyExpressed
Other,product
Other,variables
Other,moreTargetedAdjuvantTreatments
Other,stableDrug-carrierBinding
Other,follow-up
Other,cancerDeathAmongWomenWorldwide
Other,moreRecentlyHaveDeveloped
Other,193FemaleParticipants
Other,crucial
Mechanism,associationOfPcdh10Methylation
Other,poorAdhesion
Other,discussed
Other,pathologicalSpecimen
Other,suutaneousLymphaticChannels
Resistance,dealingWithEndocrineResistanceInPatientsWithBreastCancer
Other,indicator
Other,thereforeRequired
Other,moreIntensiveFollow-up
Other,protectiveRoleOfRs5743810
Exposure,impact
Other,prediction
Other,painless
Other,scrutinised
Other,firstPatientsWithPathologicallyTumor-freeNodes
Hazard,riskFactors
Other,youngAge
Mechanism,potentialMechanismForFoxc1-inducedMetastasis
Other,issuesRelatedToTherapeuticSequencingInLocalTherapyOfBreastCancer
Image,physicallyActive
Other,willUsed
Hazard,riskStratification
Other,Diseases
Comorbidities,moreComorbiditiesThanSPatients
Other,users
Survival,flowRate
Disease,choreiformMovements
Other,troponins
Other,secretion
Other,prognosticSignificanceOfNeutrophil-to-lymphocyteRatioInPatientsWithBreastCancer
Other,function
Hazard,increasedRiskOfEndometrialCancer
Other,focus
Survival,medianProgression-freeSurvival
Other,firstDataOnPre-diagnosisConcentrationsOfSrankl
Other,77
Other,chineseExpertGroup
Other,nextMade
Other,modeled
Hazard,highlyDiverseGroupOfMalignantNeoplasiaWithPoorOutcome
SNPs,SNPs
Other,personalGoals
Chemical,diindolylmethane
Other,ageOfTreatmentMethods
Other,malign
Other,imaging
Other,screeningBehavior
Other,geometries
Disease,sexualDysfunction
Technique,breastCancerControl
Disease,OS
Other,protectiveFactor
Other,observed
Other,proposedCovariance-basedSpdMatrices
Other,ligand-bindingDomainAllInBreastCancerSamplesFromPatientsPreviouslyTreatedWithEndocrineTherapy
Susceptibility,acuteDangerToMother
Other,p
Radiotherapy,radiotherapy
Other,contrastAgents
Other,characteristics
Other,2012AtBreastClinicOfPortugueseInstituteOfOncologyInPorto
Other,Delays
Variants,variants
Other,mostFrequentlyDiagnosedCancer
Other,coverage
Other,considered
Other,lymphedemaPatients
Other,evolveTowardLessSurgery
Other,properImaging
Other,understudiedPattern
Hazard,hazardRatiosWith95PercecntConfidenceIntervals
Overexpression,Overexpression
Other,2009-13
Other,immediateUnmetNeed
Other,manifold
Other,specificCancerCell-relatedComponents
Township,prognosisOfPatientsWithMaleBreastCancerInShanxiProvinceOfChinaFrom2007To2016
Other,hasProposed
Township,township
Other,created
Other,tanUsage
Other,analyses
Syndrome,syndrome
Survival,survivalRate
Technique,excellentRegionalControl
Other,NAC
Other,vap-1StainingResults
Other,SVM-BRC
Other,survivalData
Other,usExaminations
Protocols,treatmentProtocols
Other,tumorSize
Other,estrogen-aloneArmOfWhi
Other,visits
Other,followed
Other,zero-inflatedPoissonRegression
Other,fiveYearRfsrate
Other,992PercecntOfCases
Other,0.02
Other,doublingTimeOfOccult
Other,andfemales
Other,dataOfN=
Care,perceptionOfQualityOfCareProvidedByCancerCareNetworkForEarlyDetectionOfBreastCancer
Other,its
Other,diagnosisOfCancer
Disease,HT
Other,expression
Other,itsPoorPrognosis
Disease,anxiety
Other,recentlyHaveUsedAsBiomarkers
Other,lowCtnLevels
Symptom,effect
Other,young
Other,v-gCalciumChannelBindingAntibodies
Other,reducedBaselineCardiacFunction
Other,
Other,impededApoptosis
Sites,otherSites
Sites,sites
Other,promising
Other,ongoingTrials
Hazard,surgicalOutcome
Other,historyOfBreastCancer
Technique,2-groupRandomizedControlTrial
Care,clinicalCharacteristicsOfCareOfBreastCancerPatients
Disease,cancerGenomeAtlas
Other,cutaneousManifestationsOfBreastCancer
Other,thatOfMir-511
Exposure,questionnaireBasedOnAnderson'SdelayModel
Survival,obtainedFrom66FemalePatientsWithMAtDifferentTimeIntervalsForEvaluationOfCtcsByFlowCytometry
Other,dnaMethylationDifferencesBetweenTumorBreastTissue
Gene,BRCA1
Phenotype,phenotypeExpression
Hazard,coxProportionalHazardRegressionModels
Hazard,resultCompatibleWithMetastasisToOrbit
Other,performed
Gene,VEGF-D
Other,influenceOfSleepQualityOnPmInPatientsTreatedWithHt
Other,determining
Disease,tumors
Atypia,atypia
Other,recurrence
Disease,breastCancerDiagnosis
Other,medianDiagnosisAge
Other,commonMalignantDisease
Other,broadcasted
Cell,cellCycleArrestFollowedByMassiveCellDeath
Other,massMedia
Other,subgroupVariables
Other,tamoxifen-resistanceInErCancerCells
Other,likelihood
Other,threeYearsBeforeAge64Years
Other,tripleAssessmentFollowed
Other,She
Cytology,cytology
Resistance,resistance
Other,6084Years
Hazard,increasedRiskOfMortality/relapse
Other,HADS
Other,age-basedScreeningPrograms
Other,highlySensitiveNano-biosensor
Other,sialicAcidExpression
Other,moreDesirable
Other,highIndex
Other,sameRangeAsCasesWithoutWavelength-dependentMeasurementErrors
Other,yoga
Other,alternativeContrast-enhancedScreeningTools
Care,healthcareCost
Other,englishLiterature
Other,byDevelopmentOfHybridomaTechnologyHaveProducedInManyLaboratories
Other,.021
Toxicity,increasingNumber
Hazard,earlyBiomarkersOfBreastCancerRisk
Other,assay
Other,mostPatients
Other,minimal
Other,mostCountries
Other,-916
Susceptibility,healthExpectancyOfItspopulation
Other,nirProbe
Susceptibility,tertiarySexualHealthCenters
Other,sevenWomen
Care,careProvider
Other,selectiveBinding
Other,combinedAnalysis
Other,efficientSignaturesForClinicalDiagnosis
Other,biocharacter
Cell,activityOfCellProliferationInBreastCancerCells
Other,southernPortuguese
Other,cancerAssociatedFibroblasts
Other,novelty
Other,comparison
Other,empiricalTreatmentsBasedOnClinical-pathologicalCharacteristicsToUseOfTargetedApproaches
Other,main
Other,Targeting
Other,D538G
Other,typicalHormone-dependentTumor
Other,89FfdmCases
Other,extensiveMolecular
Biopsy,slnBiopsy
Other,selectedPatients
Other,estrogenReceptor
Susceptibility,proactiveManagementOfPsychologicalHealth
Other,quadrantectomy
Other,clb-pt-clbProdrug
Other,12331Non-nsaidUsers
Hereditary,11HereditaryBreastCancerGenes
Other,chlorambucilPlatinum
Hereditary,case-controlAssociationStudyForVariantsInCodingRegionsOf11HereditaryBreastCancerGenesIn7051UnselectedBreastCancerPatientsOfJapaneseAncestry
Other,Validation
Other,increasedMalignantPotential
Other,relapseRates
Other,public
Advantage,goodDiagnosticAbility
Other,heterogeneousCancerInFemalePatientsWorldwide
Other,determined
Technique,rangingFromDiagnosisPhaseToControlOfDisease
Strategy,risk-stratifiedScreeningStrategy
Other,additionallyCorrelated
Other,assessments
Assays,reporterAssays
Cytology,breastCancerGenetics
Parameters,ivimParameters
Other,navigationSurgery
Other,popular
Other,tumorUptake
Other,literature
Cytology,urgentCytology
Other,optimalCutoffValues
Other,n-typeVoltage-gatedV-gCalciumChannelBindingAntibodies
Symptom,cell-killingEffect
Other,biomarkers
Other,clinicalBreastExamination
Other,study
Other,131Percecnt
Other,Biomarkers
Other,immune-mediatedCancer-associatedDisorders
Other,patientsWithHer2
Disease,primaryTumor
Other,160Patients
Disease,invasiveBreastCarcinoma
Other,realNeedOfSurgicalTreatment
Other,Non-linearity
Other,wavelengthConsistencyIndex
Cell,canCategorized
Other,195Years
Other,practitionerDecisionmaking
Exposure,excellentPerformanceInFieldOfMedicalImagesDiagnosis
Other,pcdh10GenePromoterMethylationIdentifiedInDuctalCarcinoma
Other,adjuvantAnastrozole
Other,unbiasedRnaSequenceAnalysis
Other,baselineSt-2Level
Other,survivalDistributions
Other,proposedAlgorithm
Other,Co-existence
Hazard,outcomeInLymphedemaPatients
Other,womenWithBreastCancer
Other,treated
Other,hasInconsistent
Chemical,tamoxifen
Other,MethyLight
Other,fibroblastsAdjacent
Other,importanceOfNondestructiveTestingInDefectStudies
Other,ourAim
Other,localizedDescription
Other,experimentalStudyOfCryo-stabilityOfCancerCells
Other,agonistic/antagonisticBiocharacter
Species,patient
Other,nslnMetastasis
Other,incidenceAmongMalignancies
Other,autonomyOfPatients
Other,state-of-the-artAlgorithms
Other,interview
Image,commonAdultCancers
Radiotherapy,chemotherapyRecommendations
Other,breastCancerTissues
Other,6Months
Gene,microRNA-22
Other,hasSuggested
Other,strongContrast
Other,examination
Other,sixCirculatingMirnas
Other,hypomethylated
Other,microarrayAnalysis
Other,portugueseWomen
Other,positive
Other,baselineBpeLevels
Other,relatedResearchDataOfDiagnosisOfInoperableLocallyAdvancedBreastCancer
Other,fieldOfMedicalImagesDiagnosis
Other,profile
Cell,moreoverPerformedOnMcf-7CellLineInPresenceOfCs/bio-mofCarrier
Other,roleOfEstrogens
Other,oneExtraVisit
Other,hasAlreadyAssociatedWithDifferentCancersNon-hodgkin'sLymphoma
Other,humanLife
Other,collected
Other,serumSamplesFromCancerPatients
Survival,survivalVariance
Other,overview
Other,all
Other,betterOutcomes
Other,kaplan-meierRegressionMethods
Other,0.007
Hereditary,geneticChanges
Other,rnaKnockdown
Other,unusual
Other,following
Variants,single-nucleotideVariants
Other,16PrimaryBreastCancers
Other,poorerPrognosisInWomenWithBreastCancer
Other,threeCtcsIsolatedFromOnePatient
Other,Cryopreservation
Other,3ClinicopathologicalFactors
Other,relativeThose
Other,megakaryocyteMarker
Other,significanceLevel
Susceptibility,publicHealthChallenge
Sites,keyHypomethylationSites
Other,mStage
Other,preventionOfDiagnosedBreastCancerInEstrogen-aloneArmOfWhi
Other,cancerMolecularDiagnosis
Other,transferLearning
Other,differentPrognosis
Other,cancerCells
Other,shouldKept
Other,mir-193b-3pBinding
Other,appropriateInterpretation
Other,OP
Other,tests
Neoadjuvant,neoadjuvantSetting
Other,high
Other,mabaSurgery
Other,molecularPathwaysInvolvedInPathogenesisOfProliferation
Other,importantForDiagnosis
Other,breastCancerConfinedWithinMammaryDuctsSurrounded
Other,found
Other,r
Other,lossOf020Quality-adjustedLifeYears
Strategy,publicHealthCareSystem
Radiotherapy,isReplacedWithRadiotherapyInSituations
Other,Mechanisms
Other,antibodies
Other,nodalMegakaryocytes
Other,variableMolecularMechanismsOfCarcinogenesis
Other,recurrence-free-survival
Other,proportion
Other,YS
Cell,canEasilyExtended
Other,MicroRNAs
Resistance,importantApplicationProspects
Other,alsoAssessed
Other,Utilization
Other,mainChallenge
Other,testingDatasetsCollectedFrom48Patients
Other,aberrantDnaMethylation
Other,receivedWithoutSurfaceModification
Cell,breastTumorProgressionIncludingTumorCellGrowth
Other,field
Other,experience
Other,dscam-as1Expression
Other,13
Other,prognosticMeritOfNek6ExpressionInBreastCancer
Other,retrospectiveStudies
Hazard,breastCancerRisk
Other,percecnt
Other,anticipated
Other,effects
Other,radioisotope
Other,diagnosisOfSulinicalPrimaryCarcinomas
Mechanism,theirContraceptivePreferences
Other,mayNecessary
Other,chosen
Other,21Months
Other,relapse
Other,tumorNecrosisFactor
Other,enforcedExpression
Other,olderWomen
Strategy,antibody-basedStrategy
Other,tenfoldCross-validationMatthew
Other,tumorCells
Other,two-thirdsOfBreastCancerCases
Other,able
Other,their
Other,formulation
Other,late-stageCancerDiagnosis
Species,nudeMice
Other,specificEralpha-targetedProbe
Other,generalBreastCancerPopulation
Cell,inStudyFusedWithMouseMyelomaCellLineSp2/0InPresence
Other,greater
Other,incompleteExcisionOfMalignantTissues
Other,differentContrastAgent
Other,interference
Other,blood
Other,increase
Hazard,cancerRiskPerception
Other,onEsophagogastroduodenoscopyIdentifiedInAntrum
Other,onlyWomen
Susceptibility,pb-ctMode
Other,specificCircumstances
Other,inMultivariateModelsRelatedToPerformanceStatus
Other,Findings
Other,CTIBL
Other,inStudyDevelopedForHighlyEfficientIsolationOfCtcsFromBreastCancerPatients
Hazard,strongAssociationBetweenRs5743810AgainstRiskInSaudiArabianWomen
Symptom,goodQualityEvidence
Other,breastCancerStudies
Other,consultations
Other,subtyped
Subtype,specificSubtype
Other,intelligentTechniques
Other,score
Other,thusMeaningful
Other,pathway
Other,status
Other,48Years
Other,coding
Other,rationaleForTamsAsTherapeuticTargetInBreastCancer
Care,analysisMayAid
Other,biomarker
Other,synonymous
Other,increased
Other,hormoneReceptor-positiveTumors
Other,collapsing
Other,rnaSequenceAnalysis
Other,mutations
Other,similarSeriousAdverseEvents
Other,51Patients
Other,stratification
Disease,micrometastasis
Other,postmenopausalPatient
Other,lymphaticInvasion
Other,safety
Other,double-maintenanceTherapy
Other,onlySubgroupWithProgesteroneReceptor
Care,standardOfCareAsFirst-lineTreatmentOfPatientsWithHer2-positiveAEvenInReal-worldSetting
Other,oneRegion
Other,proliferationOfMcf-7Cells
Other,fitted
Neoadjuvant,neoadjuvantTreatment
Other,theirExperiencesLivingWithSister
Sites,hypomethylationSites
Other,deep-CNN
Hazard,cardiotoxicRisk
Other,125DogSeraSamplesIncluding75MammaryTumourSera
Other,symptoms
Other,shouldProceede
Other,undergoing
Other,individuals
Other,data
Other,comparisons
Other,surgicalExcision
Other,preliminaryGroupOfCtibl
Other,volume
Other,methods
Other,thusAimed
Technique,inexpensiveTechnique
Other,13PercecntOfDeaths
Disease,metastases
Other,mastectomy
Disease,breastCancers
Other,CTC
Signature,objectiveResponseRate
Other,Comparisons
Species,Women
Other,clearcellPlatform
Other,promisingSupplements
Other,syndromes
Other,ranging
Other,world
Other,detectionRateOfMutationsHigherThanThatDescribedInLiterature
Other,expressionInBreastCancer
Comorbidities,comorbiditiesThanSPatients
Other,utilization
Membrane,combinedPanel
Other,variousArtifactsIntroducedDuringSlidePreparation
Care,conflictBetweenCareOfMother
Other,couldIndependentPrognosticBiomarkerForMPatients'Outcomes
Variants,244GermlineVariants
Other,pre
Other,lowerInEasternThanNorthern/centralEurope
Other,based
Other,tissueStorageTime
Other,achieved
Other,OR
Other,concerns
Other,postmenopausalwomen
Other,510YearsAfterSurgery
Phenotype,closedLoopStructure
Other,challenge
Correlation,uncouplingOfInverseCorrelationBetweenBmi
Other,substantialImprovements
Image,active
Other,shaped
Other,assessed
Other,poorerPrognosis
Other,conservativeTreatment
Other,otherAgeGroups
Variants,244GermlinePathogenicVariants
Other,miR-34s
Other,Fbxo22
Other,decades
Other,targetRelationshipBetweenDscam-as1
Other,possibility
Other,Management
Signature,subtype-specificSignature
Other,it
Other,dramaticallyIncreasedAmount
Other,multicenterStudy
Other,845Percecnt
Other,targetingFxyd3-mediatedPathway
Other,localRecurrence
Other,significantlyUp-regulated
Other,ccsCoverage
Other,50
Other,clinicalPicture
Other,examined
Other,mostPowerfulTool
Hazard,multivariateCoxProportionalHazardRegressionAnalysis
Other,participantsWithBreastCancer
Radiotherapy,chemotherapyRegimens
Other,haveBackbone
Other,Applications
Other,thirdInTermsOfSpecificMortality
Radiotherapy,ourExperienceOfHigh-doseRadiotherapy
Other,peripheralBloodSamples
Township,shanxiProvinceOfChina
Other,multivariateModelsAdjustedForIncome
Other,lungMetastasesFromBreastCancerPresented
Other,pathologicallyTumor-freeNodes
Other,theirPotentialClinicalImplicationsOnBreastCancer
Other,research
Other,moreoverPoor
Other,canines
Other,identified
Symptom,effectOfDscam-as1
Exposure,finalMultipleRegressionModel
Other,presence
Other,higherResolution
Other,rapidBreast-cancer-tissueDiagnosis
Hazard,result
Other,up-regulated
Other,characterization
Other,fused
Other,haMoietyForPdt
Other,C
Cell,canStartedAtVeryEarlyStage
Susceptibility,identification
Other,commonCancer
Other,sideEffects
Other,signalIntensity
Exposure,familyImpact
Other,flankingCgi
Other,large
Other,insights
Hazard,lowerCumulativeHazardRates
Other,tnmStage
Other,respectivelyFound
Other,diseaseDefinedByTumor
Other,management
Other,Belgium
Other,procedure
Other,isSentinelLymphNodesMetastasesTo1-2Nodes
Other,therebyFrequentlyNeglected
Other,signatures
Other,selectedStandardTreatments
Other,variousEnvironments
Other,functions
Other,advancedBreastCancerBearingMutations
Other,staging
Other,vap-1NegativeStaining
Advantage,goodTolerabilitytheApatinib
Radiotherapy,chemotherapyHormonalTreatment
Other,Probes
Other,aspects
Other,secretionOfTumorNecrosisFactor
Other,related
Other,highGlut1Expression
Other,two-yearStudy
Other,reported
Other,correlationsBetweenOdds
Other,7051UnselectedBreastCancerPatientsOfJapaneseAncestry
Other,furtherStudies
Other,post-nacBpeLevels
Other,debated
Other,treatments
Other,platform
Disease,malignantPleuralEffusion
Other,protectiveFactors
Other,completionOfReproductivePlans
Survival,breastCancerPatientsWithParticularReferenceToOverallSurvivalAndrecurrenceFreeSurvivalAmongBreastCancerPatients
Other,stable
Other,extremeLearningMachineClassification
Other,inCanadaOfferedInOrganizedPrograms
Other,prognosticValue
Other,medicalStatus
Other,evaluated
Other,differentiationBetweenBreastCancerInVariousSubtypesOfBreastCancer
Other,oncogenes
Other,itInvolvesInManyCrucialMetabolicProcesses
Other,multipleSolicitations
Sites,averageOfFiveInvolvedSites
Image,mostCommonAdultCancersInKenya
Exposure,randomEffectsModel